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ABSTRACT 
 
Lipoprotein receptors are cell surface-exposed receptors that are specific for the binding and 
uptake of lipoproteins from the circulation into hepatic and extrahepatic tissues. This 
process is termed receptor-mediated endocytosis and is largely dependent upon the 
interaction between members of the so-called Low Density Lipoprotein (LDL) receptor family 
and plasma lipoproteins. The best characterized receptor of this family is the LDL receptor 
(LDLR). It plays a major role in the regulation of plasma cholesterol levels by mediating the 
binding and uptake of apolipoprotein B- (apoB) and -E (apoE) -containing plasma lipoprotein 
particles.  
To gain further insight into the molecular mechanism of LDL receptor- ligand interactions, I 
performed the present study in the domesticated chicken (Gallus gallus), which serves as an 
excellent model organism for research on lipid metabolism. Various surface receptors 
homologous to members of the mammalian LDLR family have been discovered in this 
species, and are recognized as important in the maintenance of systemic lipid homeostasis 
and embryongenesis including follicle development and oocyte growth. In 2003, the first 
avian LDL receptor ortholog was characterized and revealed a high degree of conservation 
during evolution, since the LDLR’s hallmark properties are already present in the chicken 
protein. The numerous avian and mammalian relatives of the receptor family share 
characteristic similarities, both in structural and functional terms. Via highly conserved 
cysteine-rich repeat elements in the extracellular ligand-binding domain the receptors are 
able to bind many unrelated proteins, such as apolipoproteins, proteases, signaling 
molecules, and several other groups of proteins. Acting as cargo transporters, members of 
this receptor family are not only capable of transporting macromolecules, but also of signal 
transduction. 
 
According to previous studies, certain chicken receptors belonging to the LDLR family are 
able to bind apolipoprotein E, a protein of mammalian origin, which is not produced in the 
avian species, while other receptors like the chicken LDLR do not have binding affinity for 
apoE. In agreement with previous investigations, this observation indicates that certain 
variations in the ligand-binding domain of the receptor contribute to the recognition of a 
variety of heterogeneous ligands. In the present study I focused on the investigation of 
structural differences between apoE-binding competent and apoE-binding incompetent 
receptors that are pivotal for ligand-binding. To address these issues I generated receptor 
fragments of the chicken LDLR consisting of the ligand-binding region. Based on previous 
findings derived from extensive studies of the human LDLR, mutations in putatively 
important receptor domains that were characterized as critical for apoE binding were 
introduced. Following bacterial expression, the receptor mutants were purified using affinity 
chromatography. Since the functionality of the LDLR depends on the correct folding 
including disulfide bond formation, the main challenge was to re-fold the recombinant 
receptor fragments into a binding-active conformation. This was achieved by the assistance 
of the receptor-associated protein (RAP), a molecular chaperone especially acting on LDLR 
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family members. The refolding procedure was performed in the presence of RAP in an 
environment that allows disulfide bond formation and Ca2+ incorporation. Finally, the 
mutated receptors were characterized with regards to the ligand-binding properties towards 
apolipoprotein B and -E containing lipid particles. The data obtained from solid phase 
binding assays revealed that the first LA repeat is not required to bind apoB- containing 
lipoproteins. However, mutations in the linker region separating repeat 4 and 5 as well as 
mutations in LA repeat 5 dramatically impaired the binding of apoB-containing lipoproteins. 
Initial investigations examining the binding activity of the mutant receptors towards apoE-
containing particles did not lead to reproducible results and thus require further 
investigations.  
These data obtained in an oviparous species contribute to the understanding of LDLR-ligand 
interactions and are in agreement with previous investigations, in which the importance of 
LA5 for ligand recognition of the human LDLR was established.  
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ZUSAMMENFASSUNG 
 
Lipoproteinrezeptoren sind Plasmamembranproteine, welche für die spezifische Bindung 
und Aufnahme der im Blutkreislauf zirkulierenden Lipoproteine in hepatische und 
extrahepatische Gewebe verantwortlich sind. Dieser physiologische Vorgang wird als 
rezeptorvermittelte Endozytose bezeichnet und basiert auf der Interaktion zwischen 
Mitgliedern der sogenannten Low Density Lipoprotein (LDL) Rezeptor Familie und 
Lipoproteinen im Plasma. Der als erster entdeckte und am besten charakterisierte 
Lipoproteinrezeptor ist der LDL Rezeptor (LDLR). Dieser Rezeptor spielt eine wichtige Rolle in 
der Regulation der Cholesterinspiegel durch die Bindung und Internalisierung von 
Lipoproteinen, welche Apolipoprotein- B (apoB) und /oder -E (apoE) als Proteinkomponente 
besitzen.   
 
In der vorliegenden Arbeit wurde das legende Huhn, ein gut etablierter Modellorganismus 
zur Erforschung des Lipidstoffwechsels, herangezogen um die Interaktion des LDL Rezeptors 
mit Apolipoprotein B- und -E hältigen Lipoproteinen näher zu charakterisieren. Früheren 
Studien zufolge gibt es zahlreiche  Oberflächenrezeptoren im Huhn, die eine deutliche 
Homologie zur Familie der LDL Rezeptorproteine von Säugern aufweisen. Der zum 
menschlichen LDL Rezeptor homologe Rezeptor im Huhn wurde erstmals im Jahr 2003 
beschrieben und weist die klassischen Strukturmerkmale der Säuger-LDL Rezeptoren auf, 
was auf eine hohe evolutionäre Konservierung deutet. Alle Mitglieder der LDL 
Rezeptorfamilie besitzen einen charakteristischen modularen Aufbau aus vier bis fünf 
unterschiedlichen Domänen. Die amino-terminale Region enthält die 
Ligandenbindungsdomäne des Rezeptors und besteht aus mehreren cysteinreichen 
Abschnitten, den sogenannten LA-repeats, welche die Interaktion mit verschiedenen 
Proteinen, wie Apolipoprotein, Proteasen und Signalproteinen vermitteln. 
Mutationsanalysen zeigen, dass die einzelnen Repeats unterschiedliche funktionelle 
Bedeutungen bei der Ligandenbindung besitzen.  
 
Bindungsstudien im Hühnersystem ergaben, dass einige Rezeptoren der LDLR Familie 
Apolipoprotein E binden, ein in Säugern, jedoch nicht im Huhn produziertes Protein. Andere 
Rezeptoren wiederum besitzen diese Bindungseigenschaft nicht. Dieses unterschiedliche 
Verhalten weist darauf hin, dass bestimmte Variationen in der ligandenbindenden Domäne 
des Rezeptors einen entscheidenden Einfluss auf die Ligandenbindung besitzen. In der 
vorliegenden Arbeit habe ich mich damit beschäftigt, die strukturellen Unterschiede 
zwischen ApoE-bindenden Rezeptoren und Rezeptoren, welche die Fähigkeit ApoE zu binden 
nicht besitzen, zu ermitteln. Gemäß den Ergebnissen aus früheren Mutationsanalysen wurde 
die Ligandenbindungsdomäne des Hühner- LDLR an vermeintlich wichtigen 
Bindungsregionen mutiert. Die bakteriell exprimierten mutanten Rezeptorproteine wurden 
durch Affninitätschromatographie gereinigt und, um die physiologische Funktionsweise zu 
erlangen, einem Faltungsprozess unterzogen, welcher durch das molekulare Chaperon RAP 
(Receptor-associated Protein) unterstützt wurde. Schließlich wurden die Rezeptormutanten 
hinsichtlich der Ligandenbindung von Apolipoprotein B- und -E -hältigen Lipoproteinen 
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untersucht. Diese Bindungsanalysen ergaben, dass das erste cysteinreiche LA Repeat (LA1) 
nicht an der Binding von Apolipoprotein B beteiligt scheint. Indessen führten Mutationen in 
den Repeats 4 und 5 (LA4, LA5), sowie in der Linker-Region zwischen diesen Repeats zu 
erheblichen Einschränkung bezüglich der Bindung von ApoB-hältigen Lipoproteinen. 
Bindungsanalysen zur Erforschung der Interaktion zwischen ApoE und den 
Rezeptormutanten lieferten bisher keine reproduzierbaren Ergebnisse, und erfordern daher 
weitere Untersuchungen.  
Die Daten, die im Zuge dieser Arbeit durch Experimente im Huhn ermittelt wurden, tragen 
zum Verständnis des molekularen Mechanismus der LDL Rezeptor-Ligand Interaktion bei und 
stehen im Einklang mit Untersuchungsergebnissen am menschlichen LDL Rezeptor, welche 
eine große Bedeutung des fünften LA Repeats (LA5) für die Ligandenbindung beschreiben.  
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1. INTRODUCTION 
Lipoproteins are macromolecular structures that facilitate the transport of water-insoluble 
lipids and other lipophilic components in the aqueous environment of the circulatory 
system.  While free fatty acids are bound to albumin, cholesterol, triglycerides, and 
phospholipids are packaged into lipoprotein complexes in order to allow the transport to 
various tissues and cells requiring lipids. Various distinct lipoproteins can be classified, which 
differ in size, lipid composition and protein content and account for distinct physiological 
functions.  
 
1.1 THE MAJOR PLASMA LIPOPROTEINS 
In general, all lipoproteins share a common structural organization and are widely conserved 
across distinct species. The spherical particles are composed of a neutral lipid core 
containing triacylglycerols (TG), cholesteryl-esters (CE) and small amounts of unesterified 
cholesterol.  To allow water solubility, the inner core is surrounded by a surface monolayer 
consisting of amphiphatic lipids, mostly phospholipids, and unesterified cholesterol, and 
apolipoprotein molecules. Based on their size, density, as well as lipid- and apolipoprotein 
composition, lipoproteins can be categorized into five classes: chylomicrons (CM), very low 
density lipoprotein (VLDL), intermediate density lipoprotein (IDL), low density lipoprotein 
(LDL), and high density lipoprotein (HDL). The density of these lipoproteins is inversely 
correlated with the particle’s lipid content and direct proportional to the protein contents. 
These protein components are characteristic for each lipoprotein class and their distribution 
among various classes are indicated in figure 1.1. 
Figure 1.1 Major Lipoprotein classes and their composition 
The major lipoprotein classes are categorized according to their density. Particle diameters range 
from 6000 Å for CM to 70 Å for HDL. The various classes of lipoproteins are characterized by varying 
contents of triglycerides, cholesterol, phospholipids and apolipoproteins. (Jonas, A. and Phillips, M.C. In 
Biochemistry of Lipids, Lipoproteins and Membranes, (D.E. Vance and J.E. Vance), 5th Edition, 2008) 
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The processes of lipoprotein metabolism have been intensively studied. In the following I will 
briefly summarize the main aspects of the underlying pathways. Chylomicrons (CM) and 
VLDL are the major carriers of triglycerides and are synthesized and secreted by the intestine 
(CM) and liver (VLDL). When these particles enter the blood system, they are immediately 
hydrolyzed by the enzyme lipoprotein lipase (LPL). Thereby, free fatty acids are released, and 
so-called remnant particles are formed. Free fatty acids bound to albumin are transported to 
adipocytes and muscle cells, where they are catabolized or restored as triglycerides, 
respectively. Remnant particles are rapidly cleared from the blood trough receptor-mediated 
endocytosis by the liver or are further acted on by lipases, leading to LDL particles that are 
finally removed by the liver.  
Another class of lipoproteins, high density lipoproteins (HDL), are synthesized and assembled 
in the liver and intestine and play an important role in mediating the so-called reverse 
cholesterol transport. They are responsible for the removal of excess cholesterol from 
peripheral tissues and for the transport to the liver and steroidogenic tissues, either for 
metabolism or for exretion (reviewed by Fielding, C.J. and Fielding, P.E. 2008). 
 
1.2 APOLIPOPROTEINS AND ROLES IN METABOLISM 
Lipoprotein metabolism is regulated and controlled by specialized apolipoprotein 
constituents residing on the distinct lipoprotein classes. These apolipoproteins are involved 
in the transport and redistribution of lipids and determine the cellular uptake of lipoproteins 
by interaction with various cell surface lipoprotein receptors. Apolipoproteins act as a 
scaffold for the assembly of lipoproteins and contribute to the structural stability of the 
particles. Some apolipoproteins act as cofactors and regulate the activity of enzymes that 
modify lipoproteins in the circulation (Mahley R.W., Innerarity, T.L. et al. 1984). For an 
overview, see Table 1.1.  
The apolipoproteins found in the plasma can be classified into two types: the non-
exchangeable and the exchangeable or soluble apolipoproteins. Apolipoprotein B (ApoB-100 
and apoB-48) is a very large and water-insoluble protein belonging to the group of non-
exchangeable proteins. ApoB-100 and apoB-48 are the principal protein components of LDL, 
VLDL, and chylomicrons (CM), and after synthesis and assembly they enter the circulation, 
where the lipoproteins are processed and cleared from the circulation via specific receptors 
(Jonas, A. and Philips, M.C. 2008). In contrast, the exchangeable apolipoproteins including 
apolipoproteins A, -CI-III, and -E, are secreted in lipid-free or lipid-poor forms and can 
acquire lipids in the circulation (Pownall, H.J. and Gotto, A.M. 1992).  They are soluble, 
amphihilic proteins that have much smaller molecular masses compared to apoB, thus 
facilitating the transfer and exchange among various lipoprotein particles in the plasma 
(Saito, H., Lund-Katz, S. et al. 2004).  
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Apolipoprotein 
Chromosomal 
localization 
MW 
(kDa) 
Primary 
source 
Lipoproteins Function 
ApoA-I 11 28 liver, intestine CM, HDL 
reverse cholesterol 
transport, LCAT activator 
ApoA-II 1 17 liver HDL potential Inhibitor of LCAT 
ApoA-IV 11 45 liver, intestine CM activator of LCAT 
ApoA-V 11 40 liver 
CM, VLDL, 
HDL 
regulator of plasma TG-level 
ApoB-48 2 242 intestine CM TG transport 
ApoB-100 2 512 liver 
VLDL, IDL, 
LDL 
TG-and cholesterol 
transport, interaction with 
LDLR 
ApoC-I 19 7 liver 
CM, VLDL, 
HDL 
activation of LCAT 
ApoC-II 19 9 liver 
CM, VLDL, 
HDL 
activation of LPL 
ApoC-III 11 9 liver 
CM, VLDL, 
HDL 
inhibitor of LDL 
ApoE 19 34 liver, brain 
CM, VLDL, 
HDL 
reverse cholesterol 
transport, interaction with 
LDLR + other family members 
 
Table 1.1 Summary of human apolipoproteins and their functional roles 
(Jonas, A. and Philips, M.C. In Biochemistry of Lipids, Lipoproteins and Membranes, (D.E. Vance and J.E. Vance), 5th Edition, 
2008) 
 
 
1.3 APOLIPOPROTEIN E (APOE) 
1.3.1 Gene Organization, Synthesis and Expression Profile 
Apolipoprotein E was discovered in the early 1970’s as a protein of triglyceride-rich 
lipoproteins in the plasma (Utermann, G. 1975). Immediately it became evident that it is an 
important determinant in lipid metabolism and cholesterol homeostasis. The encoding gene 
has been mapped to the human chromosome 19 (19p13.2), where it is located at the 5’ end 
of the gene cluster with apoCI, apoCII and apoCIV. The apoE gene contains four exons 
separated by three introns and specifies for a secretory protein that follows the classical 
pathway for secretory protein synthesis and release. Its complete amino acid sequence was 
elucidated by Rall et al. 1982 (Rall, S.C., Weisgraber, K.H. et al. 1982) and revealed apoE as a 
polypeptide of 299 amino acids with a molecular mass of 34 kDa. The primary translation 
product is 317 amino acids long and contains an 18 amino acid signal peptide that directs the 
nascent polypeptide to the endoplasmatic reticulum (ER). The protein is then transported to 
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the Golgi compartment, where it undergoes O-linked glycosylation with the addition of 
carbohydrate chains containing sialic acid prior to secretion (reviewed by Greenow, K., 
Pearce, N.J. et al. 2005). 
Unlike other apolipoproteins, apoE is synthesized by various tissues including kidney, spleen, 
lung, ovaries, adrenals, skin, and muscle, but its highest concentration can be found in the 
liver and the brain (Elshourbagy, N.A., Liao, W.S. et al. 1985). Belonging to the family of 
exchangeable apolipoproteins, apoE distributes in the circulation and associates with 
chylomicrons, chylomicron remnants, VLDL, and a subset of HDL lipoproteins.  
 
1.3.2 Structural Properties 
Structural analyses  have revealed that apoE is composed of two structurally and functionally 
independent domains, a 22 kDa N- terminal domain (residues 1-191) and a 10 kDa C-
terminal domain (residues 216-299) linked by a protease-sensitive hinge region (figure 1.2). 
These two domains have been characterized to fold independently and to account for 
distinct functions: While the N-terminal domain is responsible for low density lipoprotein 
(LDL) receptor binding, the C-terminal domain contains the major lipid-binding region and is 
responsible for association with lipoproteins. 
The amino-terminal domain displays an ordered structure forming a bundle of 4 elongated 
α-helices, in which the helices are arranged in an antiparallel manner with their hydrophobic 
faces oriented towards the center of the bundle. This molecular architecture provides the 
structural basis for the considerable solubility of this protein in its lipid-free state in the 
aqueous phase. 
 
 
 
Figure 1.2 Schematic overview of human apoE 
The 299-amino acid apolipoprotein E is composed of two independently folded domains: an N- 
terminal domain (residues 1-191) including the receptor-binding region and a C-terminal domain 
(residues 216-299) that contains the major lipid-binding domain. The two domains are linked by a 
protease-sensitive hinge region.  (modified from Bu, G. 2009) 
 
 
A cluster of basic amino acids between residues 136 and 150, located in the fourth helix of 
the N-terminal domain globular helix bundle structure has been elucidated to mediate 
receptor binding. The positively charged lysine- and arginine-residues have been implicated 
in the interaction with the negatively charged residues within the LDL receptor. ApoE has 
two heparin-binding sites (residues 129–169, 202–243) mediating the high affinity binding to 
heparan-sulphate proteoglycans (HSPG) (Weisgraber, K.H., Rall, S.C. et al. 1986).  
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In contrast to the N-terminus, the structural organization of the C- terminal domain of apoE 
is only poorly defined. This domain is predicted to be arranged in three amphiphatic α-
helical structures featuring properties typical of other soluble and exchangeable 
apolipoproteins for switching reversibly between a lipoprotein-bound and a lipid-free state. 
In the absence of lipids, apoE exists as a tetramer, and this tetramerization is thought to be 
mediated by the C-terminal domain. Mutational analysis revealed the highly hydrophobic 
residues 267-299 to be responsible for the self-association of apoE (Westerlund, J.A. and 
Weisgraber, K.H. 1993). The lipid binding region ranges from residues 244-272 and is 
responsible for the association apoE with lipids, which is required for its high affinity binding 
to the LDL receptor.  
 
Upon lipid binding, apolipoprotein E adopts a different, favourable conformation for 
receptor-binding by exposing the hydrophobic faces of its amphiphatic helices for interaction 
with lipid molecules. A number of studies indicated that apoE displays a high conformational 
heterogeneity after complexation with lipoproteins of varying size and shape. Therefore, the 
receptor binding affinity of apoE-containing lipoproteins depends on particle size, lipid 
composition, and the presence of other apolipoproteins (reviewed by Hatters, D.M., Peters-
Libeu, C.A. et al. 2006).  
 
Figure 1.3 Model of two possible conformations of lipid-associated apoE 
The initial binding step of apoE to lipid particles occurs through amphiphatic α-helices in the C-
terminal domain or the N-terminal helix bundle (left). The second conformation is achieved by the 
opening of the helix bundle resulting in a structure, which allows receptor interactions.  (Saito, H., Lund-
Katz, S. et al. 2004).  
 
 
ApoE displays two distinct lipid-bound states with the N-terminal four-helix bundle in either 
open, receptor-active or closed, receptor-inactive conformations (figure 1.3). Recently it has 
been sugggested that apoE-lipid binding involves a two-step mechanism, in which the initial 
binding occurs through amphipatic α-helices in either the C- terminal domain or N-terminal 
helix bundle. In the second step, the N-terminal domain undergoes a conformational 
opening, converting hydrophobic helix-helix interactions to helix-lipid interactions and 
resulting in a receptor-accessible structure. In this confirmation the positive electrostatic 
potential in the receptor-binding region is increased, thus enhancing the interaction with 
acidic elements of the LDLR (Saito, H., Lund-Katz, S. et al. 2004).  
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This model is compatible with the nature of exchangeable apolipoproteins, as the initial 
binding is readily reversible and allows rapid dissociation and exchange. Since the LDLR does 
not recognize apoE in its closed conformation, it is expected that only molecules that 
achieve the above described step2-binding will act as effective ligands for the LDLR (Nguyen, 
D., Lund-Katz, S. et al. 2009). 
 
 
1.3.3 Physiological Roles 
ApoE and Plasma Lipoprotein Metabolism: 
ApoE is involved in many steps of lipoprotein homeostasis. Its primary role is to transport 
and deliver lipids from one tissue or cell type to another through the uptake via receptor-
mediated endocytosis. ApoE is synthesized primarily in the liver as a component of VLDL, 
and as an exchangeable apolipoprotein it redistributes to enrich other lipoprotein particles. 
Serving the transport of dietary triglycerides and cholesterol, chylomicrons are synthesized 
by the small intestine, a tissue that does not produce apoE. During circulation through the 
capillaries both lipoproteins, VLDL and chylomicrons are lipolyzed on the surface of 
endothelial cells by the action of lipoprotein lipase (LPL) releasing fatty acids serving as 
energy source. In the course of this process a spectrum of particles of decreasing size and 
TG-content is produced including VLDL- remnants, CM- remnants and intermediate density 
lipoprotein particles. During lipolysis these remnants become enriched in apoE. Acting as a 
ligand for the LDL receptor and its family members, apoE promotes the uptake of 
cholesterol- enriched plasma lipoproteins by the liver, especially of VLDL and CM-remnants 
(Mahley, R.W. and Rall, S.C. 2000).  
ApoE was assigned an important atheroprotective function via facilitating the reverse 
cholesterol transport by allowing cholesteryl-ester (CE)-rich core expansion in HDL.   ApoE 
can be found on certain HDL subclasses, either as sole apolipoprotein or in combination with 
apoA-I. While apoA-I - containing HDL can accommodate only a limited amount of 
cholesteryl-esters (CE) in its core, the size and the CE- content of apoE- containing HDL can 
be significantly increased. This core expansion is attributable to the different interaction of 
apoE and apoA-I with lipids (Mahley, R.W, Huang, Y. et al. 2006). Since apoE is an effective 
ligand for LDLR, these apoE-enriched HDLs can deliver cholesterol from the peripheral cells 
to the liver via hepatic LDL receptors. 
In addition to its ligand function, apoE can affect other aspects of lipoprotein metabolism. 
High levels of apoE restrict VLDL lipolysis by displacing the lipoprotein lipase activator 
protein CII from the particles. ApoE may also influence the activity of enzymes involved in 
lipoprotein metabolism such as hepatic lipase (HL), cholesteryl ester transfer protein (CETP) 
and lecithin-cholesterin-acyltransferase (LCAT) (reviewed by Getz, G.S. and Reardon, C.A. 
2009).  Independent of its role in lipoprotein clearance, apoE plays an important regulatory 
role in the assembly and secretion of VLDL by the liver in that overexpression and 
accumulation of hepatic apoE cause hypertriglyceridemia by stimulating hepatic VLDL-
triglyceride secretion (Mensenkamp, A.R., Havekes, L.M. et al. 2001). 
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ApoE in Neurobiology: 
The largest extrahepatic source of apoE is the brain, where it acts as a principal lipid 
transport protein in the cereprospinal fluid. ApoE plays an important role in the central 
nervous system. Since Corder and colleagues (Corder, E.H., Saunders, A.M. et al. 1993) 
observed that apoE4, one of the three apoE isoforms, is the major susceptibility gene 
associated with 40-65% of cases of sporadic and familial Alzheimer’s disease (AD), the basis 
for the role of apoE and its polymorphisms in neuronal function and AD has become the 
subject of intense research (Mahley, R.W. and Rall, S.C. 2000). 
ApoE- containing lipoprotein particles are predominantly produced by astrocytes and to 
some extent by microglia (Pitas, R.E., Boyles, J.K. et al. 1987; Uchihara, T., Duyckaerts, C. et 
al. 1995) to deliver cholesterol and other essential lipids to neurons through members of the 
LDL receptor family.  
According to current views, neuronal expression of apoE is likely induced during peripheral 
nerve injury due to various toxic stimuli including oxidative stress, trauma, and ischemia. 
ApoE is involved in the repair process by redistributing lipids to regenerate neurons and 
Schwann cells, additionally it modulates neurite extension and cytoskeletal function 
(Greenow, K., Pearce, N.J. et al. 2005).  
 
 
ApoE and Immunoregulation: 
Muliple studies indicate that apoE can modulate key elements of the immune response, 
either positively or negatively (Getz, G.S. and Reardon, C.A. 2009). ApoE -/-  mice are more 
susceptible to bacterial infections and display an impaired immune system. There is 
increasing evidence that apoE has an effect on the susceptibility to parasitic and viral 
infections (Mahley,R.W. 2009). Several viruses bind to cell surface heparan sulfate 
proteoglycans (HSPGs) as an initial event of infection. It seems possible that the ability of 
apoE to prevent infection can be explained by the competition of apoE for HSPGs (Mahley, 
R.W. and Rall, S.C. 2000). In HIV- positive patients, apoE4 homozygosity was shown to 
accelerate progression to AIDS and to increase susceptibility to opportunistic infections 
(Mahley, R.W., Weisgraber, K.H. 2009). Further studies are underway to gain a better insight 
in the underlying molecular mechanism.  
 
 
1.3.4 ApoE Polymorphisms and Pathophysiological Implications 
Human apoE exists in 3 isoforms, E2, E3 and E4, which differ by single amino acid variations 
at positions 112 and 158 (Fig. 1.4 and Table 1.2). ApoE3, the most common form, contains 
cysteine at position 112 and arginine at position 158, whereas E2 contains cysteines and E4 
arginines, respectively, at both sites. The most common phenotype in the human population 
is E3 with an allelic frequency of 78%, followed by E4 with 15% and E2 with 7 %. These single 
amino acid substitutions alter the protein’s structure and influence its lipid association and 
receptor binding. All 3 isoforms adopt a four helix bundle motif, but there are subtle 
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differences in the side-chain conformations and salt-bridge arrangements of the isoforms 
that have profound effects on their structure and biophysical properties.   
 
Figure 1.4 Model of the structure of lipid-free apoE 
The N-terminal domain consists of a four helix-bundle (1, red; 2, blue; 3, green; 4, yellow). The LDLR-
binding region resides on helix 4. The N-terminus also contains the polymorphic positions 112 and 
158 that distinguish the three common isoforms. The C-terminal domain (gray) contains the main 
lipoprotein-binding elements. (Hatters, D.M., Peters-Libeu, C.A. et al. 2006) 
 
 
The various isoforms were determined to have distinct lipid binding properties. ApoE2 and 
E3 preferentially bind to small, cholesterol-rich high density lipoproteins (HDL), whereas 
apoE4 prefers lower density lipoproteins, such as VLDL and LDL (Dong, L-M. and Weisgraber, 
K.H. 1996). This difference in lipoprotein binding appears to be determined by interactions 
of the C- and the N-terminal domains. In apoE4, these domains interact with each other in a 
unique manner unlike they do in no other isoform. The arginine at position 112 causes a 
rearrangement in the side chain of arginine at position 61 within the N-terminal domain of 
apoE4. This shift in the side chain orientation allows Arg61 to interact with an acidic residue 
(Glu255) within the C-terminus. This domain interaction mediates a closer contact between 
the N-and C-terminal domains, which does not occur to the same extent in apoE2 or apoE3, 
where the different conformation of the Arg61 side chain is less accessible for salt bridge 
formation. (Mahley, R.W. and Rall, S.C. 2000) 
 
Several studies investigating the chemical and thermal stability of apoE revealed isoform- 
specific effects. ApoE isoforms differ considerably in the stability of the N- terminal domain 
with apoE2 showing the highest, apoE3 intermediate, and E4 only low resistance against 
chemical and thermal denaturation. This observation indicates that replacing cysteine- by 
arginine residues results in a cumulative decrease in the stability of the helical bundle 
(Acharya, P., Segall, M.L. et al. 2002).  
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Additional isoform-specific variations of apoE concerning its own expression and that of 
plasma lipids were assessed. ApoE2 is associated with decreased levels of apoB and 
cholesterol and increased levels of apoE and triglycerides (Mahley, R.W. and Rall, S.C. 2000). 
On the other hand, apoE4 tends to be associated with increased apoB and cholesterol levels 
and decreased apoE levels. While the variation in cholesterol levels can be attributed to the 
different affinities of the isoforms for the LDLR, the mechanisms causally related to these 
changes are currently poorly understood (Mahley, R.W. and Rall, S.C. 2000). For a summary 
of the main properties of the apoE isoforms, see Table 1.2. 
 
 
Isoform Allelic 
frequency 
Amino acid 
variation 
112           158 
LDL-receptor 
affinity 
Lipoprotein-
binding 
preference 
Associated disorders 
ApoE2 7 % Cys Cys Low HDL Type III hyperlipoproteinemia 
ApoE3 78 % Cys Arg High HDL unknown 
ApoE4 15 % Arg Arg High VLDL, LDL Alzheimer’s disease 
 
Table 1.2 Prevalence of human apoE isoforms and their key differences 
(modified from Hatters, D.M., Peters-Libeu, C.A. et al. 2006) 
 
 
A number of studies have revealed pathophysiological implications attributed to apoE 
polymorphism. In apoE2 the cysteine to arginine substitution leads to the elimination of the 
salt bridge between Arg158 and Asp154, but simultaneously a new salt bridge between 
Arg150 and Asp154 is formed. This salt bridge rearrangement lowers the positive 
electrostatic potential of the receptor-binding region, reducing the ability of apoE2 to 
interact effectively with the LDL receptor. The receptor binding activity of apoE2 was 
observed to be 50- to 100- times weaker compared to apoE3 and apoE4 (Schneider ,W.J., 
Kovanen, P.T. et al. 1981). As a result, apoE2 is associated with type III hyperlipoproteinemia, 
a lipid disorder characterized by increased plasma levels of cholesterol and triglycerides, 
xanthomas and premature cardiovascular disease (Mahley, R.W. and Rall, S.C. 2001).  
Another pronounced pathological effect attributable to apoE polymorphism is the 
association of apoE4 with neurodegenerative diseases, particularly with Alzheimer’s disease 
(AD). As a major risk factor for AD it not only increases the degree of risk, but also lowers the 
age of onset of AD (Saunders, A.M., Strittmatter, W.J. et al. 1993). Domain interaction and 
reduced stability are suggested to contribute to the association of apoE4 with disease (Dong 
L.-M. and Weisgraber, K.H. 1996; Morrow, J.A. Segall, M.L. et al. 2000), but the detailed 
mechanism is yet unclear. 
 
1.3.5 Apo E Receptors 
ApoE fulfills its function in lipid transport and delivery mainly by two receptor pathways. The 
first is the well characterized LDL receptor pathway in both hepatic and extrahepatic cells 
(see chapter 1.4.1). Via this pathway, the LDLR mediates the removal of LDL and remnant 
INTRODUCTION 
 
14 
 
lipoproteins from the circulation by binding to apoB100- and apoE-containing particles. Since 
apoE acts as ligand for all members of the LDLR family, it was anticipated that apoE plays a 
major role in the regulation of plasma cholesterol levels both in the plasma and in the 
central nervous system (Innerarity, T.L. and Mahley, R.W. 1978). 
 
 
However, the finding that the absence of normal LDLR activity led to the accumulation of 
LDL, but not of apoE-enriched remnants pointed to an additional mechanism for the hepatic 
clearance of these remnant particles independent of the LDLR (Rubinsztein, D.C., Cohen, J.C. 
et al. 1990). This function has been attributed to a receptor with a structural similarity to the 
LDLR molecule and was therefore termed LDL receptor-related protein 1 (LRP1) (Herz, J., 
Hamann, U. et al. 1988). This second, receptor pathway is proposed to take place mainly in 
the liver in order to clear apoE- containing remnant lipoprotein particles that are generated 
in the circulation by lipolytic processing of intestinally derived CM and hepatically derived 
VLDL. As these remnants are highly atherogenic, the clearance of these particles from the 
plasma is of great importance. 
 
Mahley and Huang have suggested cell-surface heparan sulfate proteoglycans (HSPGs) to be 
involved in an alternative pathway. (Mahley, R.W. and Huang, Y. 2007). They hypothesize 
that the lipoproteins are metabolized in a multistep process. First, remnant particles enter 
the perisinusoidal space (space of Disse) through the fenestrated endothelium, where they 
are captured by interaction with HSPG that are abundant in the matrix of the space of Disse 
and on the surface of hepatocytes. This binding is supposed to occur between the sulfate 
groups of proteoglycans and apolipoprotein E. Next, the remnants may undergo lipolytic 
processing by surface- or lipoprotein- bound lipases preparing the particles for uptake. 
Finally the processed particles reach the hepatocyte cell surface to bind to receptors, 
predominantly LRP1, that will internalize them. Several findings indicate that HSPG’s on the 
hepatic cell surface are involved in the process of remnant lipoprotein uptake either by 
transferring the remnant particles to LRP1 or the LDLR or by directly serving as an acceptor 
for remnant lipoprotein uptake. To date in vivo HSPG-mediated clearance of remnant 
particles has not been demonstrated (MacArthur J.M., Bishop J.R. et al. 2007). 
 
1.4 THE MAMMALIAN LDL RECEPTOR FAMILY 
The LDL receptor family is an evolutionarily conserved group of cell- surface receptors. The 
last 30 years of research have led to detailed insights into function and structure of 
lipoprotein receptors, which is now one of the best understood aspects in receptor biology. 
Since the molecular characterization of the LDLR by Brown and Goldstein, an increasing 
number of related proteins have been discovered. 
Characteristic hallmarks of LDLR family members are common structural elements, which 
show high degrees (70-100%) of sequence identity. Despite their structural homology, the 
different receptors are involved in a wide range of physiological functions in different tissues 
ranging from cargo transport function of a variety of ligands, ligand uptake through clathrin-
mediated mechanisms, to participation as receptors and co-receptors in cellular signalling 
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events. The structural organization of all LDL receptor family members is depicted in figure 
1.5. For detailed information on individual members of the LDLR supergene family see 
review by Schneider, W.J. In Biochemistry of Lipids, Lipoproteins and Membranes, (D.E. 
Vance and J.E.Vance), 5th Edition, 2008. 
 
  
Figure 1.5 Domain structures of the members of the LDL receptor family 
The LDLR family includes various cell-surface receptors with similarities in their structural 
organizations. Characteristic hallmarks are an extracellular domain (containing complement-type-, 
EGF-type repeats and O-linked sugar domains) and a short intracellular domain (harbouring the 
internalization sequence for endocytosis). Some family members also contain vacuolar protein-
sorting 10 protein (Vps10p) domains and fibronectin (FN) type-III domains (SorLA). (Andersen, O. and 
Willnow, T. 2006). 
 
 
1.4.1 The LDL receptor 
1.4.1.1 Physiological Role 
The LDL receptor was the first family member discovered; it plays a central role in systemic 
and cellular lipoprotein metabolism. Due to the pioneering work of Brown and Goldstein and 
their colleagues (Goldstein, J.L., Brown, M.S. et al. 1985) the role and mode of action of the 
LDLR in lipoprotein metabolism has been elucidated in great detail. The LDLR is an important 
determinant in the homeostasis of cholesterol by binding apolipoprotein E- and 
apolipoprotein B-100- containing lipoprotein particles and mediating their cellular uptake by 
endocytosis. The uptake of lipoproteins by the LDLR serves a dual role in lipid homeostasis. It 
delivers essential lipids required for the maintenance of cellular functions and it regulates 
the concentration of cholesterol-rich lipoproteins in the circulation. The importance of these 
functions is indicated by the large number of mutations in the LDL receptor gene leading to a 
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syndrome called familial hypercholesterolemia (FH) (Goldstein, J.L. and Brown, M.S. 1974). 
Patients with FH exhibit an increase in levels of circulating lipoproteins: on average, 
homozygous gene defects result in a four-fold and heterozygous defects in a two-fold 
elevation of mean plasma cholesterol levels. As a consequence, the hypercholesteremic FH 
patients suffer from premature atherosclerosis and coronary artery disease. 
 
The uptake of cholesterol via receptor-mediated endocytosis of LDL is one of the best 
characterized mechanisms of macromolecular transport across the plasma membrane of 
eukaryotic cells (Goldstein, J.L., Brown, M.S. et al. 1985). This cellular mechanism is termed 
LDLR pathway and is depicted in figure 1.6. 
 
 
 
Figure 1.6 The LDL receptor pathway and regulation of cellular cholesterol homeostasis 
LDL particles bind to the LDLR located in clathrin-coated pits (c.p.) and are internalized in coated-
vesicles (c.v.). These vesicles become uncoated and acidified by protons (H+), resulting in endosomes 
(end.). The low pH triggers the dissociation of the ligand –receptor complex: While the LDLR is 
recycled to the cell surface, LDLs are broken down in lysosomes (lyso.) releasing cholesterol via the 
hydrolysis of cholesteryl esters. This LDL-derived cholesterol is either subjected to the CE storage 
pool, the synthetic precursor pool or the regulatory oxysterol pool. For a detailed description see 
text. (Schneider, W.J. In Biochemistry of Lipids, Lipoproteins and Membranes, (D.E. Vance and J.E. Vance), 5th Edition, 
2008)   
 
 
The interaction of circulating lipoproteins with the LDL receptor occurs at the cell surface, 
where the receptor molecules are localized in so-called clathrin-coated pits. Clathrin is a 
protein that facilitates the formation of small vesicles within the cytoplasm and thus, 
supports the uptake of endocytic receptors. LDL particles bound to LDLR are internalized in 
clathrin-coated vesicles, which are acidified by protons resulting in endosomes, where the 
bound lipoprotein dissociates from the receptor due to the low pH. The receptor is then 
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returned to the cell surface in a process called receptor recycling. The LDL particle is targeted 
to lysosomes, where apolipoproteins are broken down into amino acids, lipids and 
cholesterol. The LDL- derived cholesterol has three main fates: (a) for further storage it is 
reconverted to cholesteyl esters by stimulating of acyl-CoA:cholesterol acyltransferase 
(ACAT), (b) it is used as biosynthetic precursor for bile acids, steroid hormones, and 
membrane synthesis, and (c) it serves several regulatory functions (mainly after conversion 
to oxysterols).  
 
 
1.4.1.2 Regulation of the LDLR 
The expression of the LDLR is controlled by a feed-back control mechanism that senses 
intracellular cholesterol concentrations. The sterol-regulated transcription factors SREBP 
(sterol response element binding proteins) play a key role in this regulatory mechanism 
(Brown, M.S. and Goldstein, J.L. 1999). Unlike other transcription factors, the SREBPs are 
synthesized as membrane-bound proteins attached to the ER. When cholesterol levels are 
low, the membrane-bound precursors of SREBPs are transported from the ER to the Golgi, 
where upon a two-step proteolytic cleavage, SREBPs are released from the Golgi membrane 
and translocated to the nucleus. There they bind to sterol regulatory elements in promoters 
and activate the transcription of various genes including those encoding the LDL receptor 
and the key enzymes for cellular cholesterol biosynthesis, HMG-CoA synthase and -
reductase. When cholesterol levels are elevated, the transport of SREBPs to the Golgi 
complex and proteolytic release of active transcription factors are prevented. Consequently, 
the transcription of the target genes declines, and the cell produces less cholesterol and LDL 
receptor molecules, thereby preventing cellular cholesterol overload (Horton, J.D. Goldstein, 
J.L. et al. 2002).  
 
 
1.4.1.3 Structural Organisation 
The LDL receptor is a highly conserved membrane glycoprotein of 839 residues encoded by a 
gene of 45 kb located on the human chromosome 19 (19p13.1-13.3).  
The mature receptor is a type I transmembrane protein consisting of five functionally and 
structurally defined modules (see Fig. 1.7). In order of appearance from the amino-terminus, 
these domains are characterized as follows: 
 
 
1) The ligand-binding domain: This domain consists of seven cysteine-rich repeats (R1-R7), 
each about 40 amino acids in length. These modules are referred to as LDL receptor type 
A (LA) repeats, or occasionally, complement-type A repeats. Nuclear magnetic resonance 
(NMR) and crystal structures of the distinct repeats revealed a two-loop conformation 
established by three disulfide bonds, characteristically between cysteine residues I+III, 
II+V and IV+VI within a LA repeat (reviewed by Gent, J. and Braakman, I. 2004). In the C-
terminal part of each LA-repeat, conserved clusters of negatively charged residues (with 
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the signature tripeptide Ser-Asp-Glu, SDE) are found. These clusters are thought to 
interact with corresponding clusters of positively charged residues in the receptor binding 
regions of apoB-100 and apoE. The seven adjacent LA-repeats are connected by short 
flexible linkers contributing to the flexibility of the LDLR and enabling the LDLR to 
accommodate its shape to bind a variety of heterogeneous lipoprotein particles (of 
different particle shape and diameter). In general, the individual ligand-binding modules 
are linked by 4-5 residues with exception of the LA-repeats 4 and 5, which are connected 
by a 12- residue linker.  
 
 
2) EGF (epidermal growth factor) precursor homology domain: The EGFP homology domain 
lies next to the ligand-binding site and is characterized by the high degree of homology 
with the precursor to epidermal growth factor (EGFP).The domain consists of two EGF-
like modules (EGF-A and EGF-B), followed by a 6-bladed β-propeller domain with a YWTD 
consensus motif at the core, and a third EGF-like repeat (EGF-C). This part of the LDLR is 
implicated in the acid-dependent dissociation of the ligands in endosomes. The acidic 
environment triggers a conformational change in the LDLR receptor leading to a closed 
structure between the β-propeller and the binding repeats LA4 and LA5, thereby releasing 
the ligand (Rudenko, G., Henry, L. et al. 2002). 
 
 
3) O-linked sugar domain: The O-linked sugar domain, located just outside the plasma 
membrane, is 58 amino acids long and enriched in serine and threonine residues. Most of 
the 18 hydroxylated amino acid side chains are glycosylated. The O-linked 
oligosaccharides undergo posttranslational elongation in the course of receptor 
maturation. Although the structure of this region is very well known, its specific function 
remains somewhat unclear (Davis, C.G., Elhammer, A. et al. 1986). 
 
 
4) Transmembrane domain: A hydrophobic domain of 24 amino acids anchors the LDLR in 
the lipid bilayer. The sequence of this domain is the least conserved of all receptor 
domains in seven mammalian species. This finding speaks against a unique function other 
than anchoring. Deletion of this domain, both in naturally occurring mutations, for 
instance, the internalization-defective receptor form – FH 274  (Lehrman, M.A., 
Schneider, W.J. et al. 1985) or by generated by site-directed-mutagenesis, leads to 
secretion of truncated receptors from the cells. 
 
 
5) Cytosolic domain: The cytoplasmic domain of the LDLR constitutes a short stretch of 50 
amino acid residues and is involved in the targeting of the LDLR to clathrin-coated pits. 
Mutational analysis revealed a dominant role for the NPxY motif (Asn-Pro-Xxx-Tyr, where 
x denotes any amino acid; in the LDLR and most frequently it is valine) as internalization 
signal recruiting a variety of adaptor- and scaffolding proteins. Recently, the cytoplasmic 
domains of the LDLR and its relatives have come into renewed focus due to their 
involvement in signalling pathways (Willnow, T.E. 1999).  
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Figure 1.7 Schematic model of the LDL receptor 
The domains of the LDL receptor from the amino-terminus (N) to the carboxy-terminus (C) are: a 
ligand-binding domain consisting of 7 cysteine-rich repeats, the Epidermal Growth Factor-Precursor 
homology domain (EGFP), the O-linked sugar domain, a short transmembrane domain and a 
cytoplasmic tail containing the internalization signal for endocytosis (NPXY). A more detailed 
description is given in the text.    
 
 
1.4.1.4 Biogenesis and Folding of the LDLR 
The LDLR is synthesized by the ribosomal machinery and the precursor of the mature 
receptor is postranslationally folded in the endoplasmatic reticulum (ER). Upon transport to 
the Golgi network, the LDLR undergoes extensive O-linked glycosylation giving rise to the 
mature 160 kDa form of the LDLR, which is finally transported to the cell surface. Because of 
the modular structure and the observation that individual modules can fold into their native 
structures, both in vivo and in vitro, folding of the LDL-receptor domains has long been 
considered to occur independently and sequentially, starting with the most N-terminal 
cysteine-rich repeat. However, it was revealed that folding of the LDLR in the ER occurs in a 
non- vectorial manner (Gent, J. and Braakman, I., 2004; Jansens, A., van Duijn, E. et al. 2002). 
Early in the folding process, the newly synthesized polypeptide chains fold rapidly into 
compact structures by the formation of non-native disulfide bonds most likely between 
cysteines of different domains. This rapid collapse may prevent unfavorable aggregation and 
interaction with other cysteine-containing proteins or LDL receptor ligands. Continuing LDLR 
folding, these non- native disulfides are reshuffled, allowing expansion of the molecule. 
Finally, in the native conformation, disulfide bonds only exist between cysteine-residues 
within individual repeats. Studies investigating the requirements for formation of native 
disulfide bonds showed that calcium ions were required for proper folding. Highly conserved 
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acidic residues near the C- terminal end of repeat 5 (R5) were identified to stabilize the 
structure by participating in the incorporation of a calcium ion. (reviewed by Gent, J. and 
Braakman, I. 2004).  
 
Chaperone-assisted folding in the endoplasmatic reticulum (ER) 
 
Through its Ca2+-rich environment and unique oxidizing potential, the endoplasmatic 
reticulum provides an optimized environment for folding, disulfide bond formation, 
maturation, and assembly of proteins. The proper folding of the LDLR is thought to be 
supported in the ER by the help of a variety of molecular chaperones and folding factors. 
These may include general chaperones like BiP, calnexin, calreticulin, as well as so-called 
private chaperones, which in the case of the LDL receptor family, is the receptor-associated 
protein (RAP). Other chaperones, e.g. Boca and Mesd, are implicated in the structural 
stabilization and facilitation of the correct folding of receptor proteins. 
 
General chaperones 
Numerous molecular chaperones function in the ER to generally ensure proper synthesis of 
proteins. This ER quality control system for newly synthesized proteins includes the 
retention of unfolded proteins in the ER, proteasome-mediated degradation of persistently 
misfolded proteins, the retrieval of misfolded proteins from later compartments of the 
secretory pathway back to the ER, and the rerouting of proteins from the Golgi apparatus to 
lysosomes. 
The well known chaperone BiP (binding immunglobuline protein) is the most abundant ER- 
chaperone that interacts non-selectively with various substrates thereby providing support 
in protein folding. BiP was identified to bind transiently to the LDLR and to retain misfolded 
mutants in the ER (Jørgensen, M.M., Jensen, O.N. et al. 2000).  
Calnexin and Calreticulin are lectin-like ER chaperones that interact specifically with 
monoglycosylated N- linked glycoproteins and play an important role in glycoprotein quality 
control. The oxidoreductases of the protein disulfide isomerase (PDI) family catalyze and 
monitor the correct formation of disulfide bonds, which is a major event in LDLR folding. 
Thus, the enzyme PDI was proposed to play a role in contributing to LDLR folding (reviewed 
by Gent, J. and Braakman, I. 2004). 
 
Private Chaperones 
The hallmark of private chaperones is that they provide support only for selected proteins or 
protein families. The receptor-associated protein (RAP) is a specialized chaperone that 
assists LDLR family members to fold correctly and traffic safely along the secretory pathway. 
It was initially discovered as a 39-kDa protein that was co-purified with LRP1 from human 
placenta (Bu, G. and Marzolo, M.P. 2000).  Immunofluorescent studies demonstrated that 
RAP was primarily localized intracellularly with 70% in the endoplasmatic reticulum and 24% 
in Golgi compartments. This observation of an intracellularly active, ER-resident protein 
proposed RAP as a trafficking chaperone/escort protein for LRP1.  
The important role of RAP was supported by studies in RAP-knockout mice, in which LRP1 
was retained as aggregates in the ER. Simultaneously, the amount of functional LRP1 in the 
liver and brain was reduced significantly (Willnow, T.E., Rohlmann, A., Horton, J. et al. 1996). 
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It was revealed that RAP functions as a chaperone and escort protein in the course of LRP1 
biogenesis. During the biosynthesis of the receptor, RAP associates with the receptor via the 
ligand-binding region and assists in the proper folding of the receptor. Following the 
subsequent trafficking, the function of RAP is to prevent the premature interaction of the 
receptor with ligands that are expressed in the same cellular compartment and thus might 
interfere with the proper folding of the receptor. Upon escorting the receptor to Golgi-
compartments, RAP dissociates from the receptor as a result of the low pH and recycles back 
to the ER.  
 
The role of RAP as a folding chaperone for lipoprotein receptors could be extended to other 
members of the LDLR family (including particularly LDLR, LRP2 and the VLDLR). Interestingly, 
RAP-assisted folding was observed to be differential among individual receptors. While RAP 
deficiency led to an impaired folding process of LRP1 and VLDLR, the folding of the LDLR 
remained largely unaffected. This finding was consistent with the lower affinity of RAP 
binding to the LDL receptor when compared with that to LRP1 and the VLDLR. It is possible 
that for an efficient folding process of the LDLR, other chaperones such as BiP or yet 
unidentified chaperones are able to compensate for RAP (Medh, J.D., Fry, G.L. et al. 1995). The 
finding that in RAP-deficient mice, the level of LDLR expression was unaffected in the liver 
(Willnow, T.E., Rohlmann, A., Horton, J.et al. 1996), but was downregulated in the brain 
(Veinbergs, I., Van Uden, E.et al. 2001) suggests that RAP-assisted LDLR folding has a 
different importance in various cells and tissues.  
 
Recently an evolutionarily conserved ER- protein was identified, named Boca in Drosophila 
and Mesd (Mesoderm development) in the mouse, acting as chaperones for LDLR receptor 
relatives in these species (Culi, J. and Mann, R.S. 2003; Hsieh, J.C., Lee, L. et al. 2003). In 
Drosophila, it was shown that Boca is essential for membrane localization of Arrow, the 
homologue of LRP5 and LRP6 in vertebrates, and of Yolkless (yl), the receptor required for 
vitellogenin uptake into the Drosophila’s oocyte (Schonbaum, C.P., Lee, S. et al. 1995; 
Schonbaum, C.P., Perrino, J.J., et al. 2000). Moreover, Boca/Mesd have been proposed as 
chaperones that are required for the correct assembly and folding of the β-propeller domain 
and of the EGF precursor domain of LRs (Culi, J., Springer, T.A. et al. 2004; Hsieh, J.C., Lee, L. 
et al. 2003).  
 
 
 
1.4.1.5 Ligand Recognition by the LDL Receptor 
Mutational analysis and binding studies revealed that the seven tandemly repeated LA 
modules are significant in the contribution to the binding of the LDLR to various ligands. 
Recombinant receptors containing only the seven LA repeats fully retain the ability to bind 
LDL, showing that the rest of the protein is not required for ligand-binding (Simmons, T., 
Newhouse, Y.M. et al. 1997). The primary sequences of repeats LA1-LA7 are ~ 40-50 % 
identical. As outlined above, each module contains three disulfide bonds and a calcium ion 
that is tightly coordinated by four conserved acidic residues at the C-terminal end of the 
module. 
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The LDL receptor binds two apolipoprotein ligands - apolipoprotein E and apolipoprotein B-
100. The receptor exhibits high-affinity binding of LDL particles, which contain a single copy 
of apolipoprotein B-100 and of β-VLDL particles containing multiple copies of apolipoprotein 
E. Although these apolipoproteins do not share structural similarities, sequence elements 
rich in positively charged amino acids are present in both. Together with the fact that highly 
conserved acidic residues within the LDLR are implicated in receptor binding, it has been 
postulated that the LDLR-ligand interaction occurs via electrostatic interactions between 
acidic residues in the receptor and basic residues within the ligand (Weisgraber, K.H. 1994).  
Mutational analysis of the LDL receptor provided evidence for a functional difference 
between distinct LA repeats (Esser, V., Limbird, L.E. et al. 1988). These investigations 
suggested that LA1 is not required for binding of either LDL or β-VLDL particles, while LA 
repeats 2+3 and LA 6+7 as well as the EGF-A repeat are required for maximal binding of LDL, 
but not of β-VLDL. LA repeat 5 was found to be crucial for the binding of both ligands. 
Further investigations established that although LA5 is required for association with apoE- 
and apoB-100 containing ligands, LA5 alone is not sufficient to mediate binding. However, 
the pair LA4 and LA5 was determined as the minimal receptor module retaining the ability to 
bind apoE- containing particles (Fisher, C., Abdul-Aziz, D. et al. 2004). Recent investigations 
by Yamamoto et al. provide support for this finding by revealing that for high affinity 
binding, the LA5 module must also exist in the correct context with respect to the other LA 
repeats within the ligand-binding region (Yamamoto, T. and Ryan, R.O. 2009).  
Moreover, the importance of LA5 is underscored by a large number of mutations localized to 
this repeat that lead to FH. In general, the LA5 repeat seems to be particularly important for 
the binding and release of LDLR ligands. This repeat contains several amino acids that are 
not present at the same location in any of the other repeats. One of the unique attributes is 
that the cluster of serine-aspartatic acids-glutamic acid (SDE) is followed by an additional 
glutamate, creating a sequence of 3 negatively charged amino acids, whereas all the other 
repeats have only two (Russell, D.W., Brown, M.S. et al. 1989). It may be possible that this 
extra negatively charged residue contributes to the specific function of LA5.  
 
Recently, another ligand that binds to the extracellular domain of the LDL receptor was 
identified, termed proprotein convertase subtilisin-like kexin type 9 (PCSK9) (Abifadel, M., 
Varret, M.et al. 2003). Several naturally occurring mutations in PCSK9 were observed, which 
lead either to a gain or loss of protein function. Loss of function mutations are associated 
with hypocholesterolemia and protect from heart disease, while gain of function mutations 
in PCSK9 lead to autosomal dominant hypercholesterolemia (ADH), a rare form of familial 
hypercholesterolemia (FH). 
The property of PCSK9 is based on the sequence-specific interaction with the EGFP repeat A 
(EGF-A) of the LDLR. As a secreted factor, PCSK9 interacts with the LDLR followed by the 
subsequent internalization of the PCSK9-receptor complex into the endosome. The binding 
of PCSK9 apparently interferes with the acid-dependent conformational change essential for 
receptor recycling. Thus, the PCSK9-bound LDLR is targeted to lysosomal degradation rather 
than recycling to the plasma membrane, which in turn results in decreased amounts of LDLR 
on the cell surface accompanied by elevated LDL-cholesterol levels.  
The precise mechanism of PCSK9 action is not fully understood yet, and is currently under 
extensive investigation. Since PCSK9 is proposed to be a new determinant in cholesterol 
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homeostasis, it constitutes a promising target for the treatment of hypercholesterolemia 
and atherosclerosis (reviewed by Lambert, G., Charlton, F. et al.  2009).  
 
 
1.5 THE CHICKEN LDL RECEPTOR FAMILY 
To date, various avian LDL receptor relatives homologous to members of the mammalian 
LDLR family have been discovered (reviewed by Schneider, W.J. 2009). Members of the LDL 
receptor gene family play crucial roles in chicken embryo development, but are also 
important in other physiologic processes in the avian species.  
In oviparous species, the developing embryo is absolutely dependent on nutrients stored in 
the egg yolk. The main components of the yolk are vitellogenin (VTG) and VLDL, which are 
produced in and secreted from the liver under the control of estrogen (Tata, J.R. 1986). 
These two yolk precursors are taken up into the growing oocyte by means of endocytosis 
mediated by receptors belonging to the LDLR family, most notably LR8, as described below. 
 
1.5.1 The chicken VLDL Receptor (LR8) 
A 95 kDa protein in the oocyte plasma membrane was identified as the major receptor for 
deposition of yolk precursors in the laying hen (George, R., Barber, D.L.  et al. 1987; Stifani, 
S., Barber, D.L. et al. 1990; Nimpf, J. and Schneider, W.J. 1991). Molecular characterization of 
this protein revealed that it is a member of the LDLR supergene family featuring all structural 
hallmark properties except for the presence of an additional (eighth) LA-repeat in the ligand-
binding domain, from which it derives its name.  
LR8 was initially anticipated to be a cell-type specific LDLR isoform, as antibodies against 
mammalian LDL receptors showed cross reactivity against the chicken oocyte receptor 
(Hayashi et al. 1989). Since the detection of the mammalian VLDL receptor (Takahashi et al. 
1992), which is characterized by an eight-repeat ligand-binding domain and the 
determination of 84% sequence identity between LR8 and the VLDLR, LR8 was confirmed to 
be a homologue of the VLDLR rather than of the LDLR (Bujo, H., Hermann, M. et al. 1994). 
The gene for LR8 is located on the chicken sex chromosome Z (Bujo, H., Hermann, M. et al. 
1994). All VLDLRs exist in alternative forms generated by differential splicing (Bujo, H., 
Lindstedt, K.A. et al. 1995). Indeed, in chicken somatic cells, LR8 is expressed as the larger 
isoform, LR8+, which contains the O-linked sugar domain, whereas the oocyte expresses the 
LR8- isoform lacking the O-linked sugar domain. The physiological relevance for this 
dichotomy is not known; interestingly, the level of expression of LR8 in oocytes is 3 orders of 
magnitude larger than that of LR8+ in somatic cells.  On the other hand, mammalian VLDL 
receptors are predominantly found in tissues with active metabolism of fatty acids, such as 
skeletal muscle, heart, adipose tissue, and brain; however, the exact range of functions 
performed by VLDLR in mammals is not known. In contrast to mammals, at least the function 
of the LR8- isoform in avian species is well established. It serves as a multifunctional receptor 
which transports lipoproteins and other components not for immediate catabolism, but for 
storage and later use as energy supply for the developing embryo. The functional 
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importance of LR8- is demonstrated by the infertile, non-laying chicken strain named R/O 
(Restricted Ovulator) carrying a single point mutation in the LR8 gene. Because of the failure 
to deposit VLDL and VTG into the oocyte, these chickens develop severe hyperlipidemia and 
atherosclerotic lesions (Nimpf, J,. Radosavljevic, M.J. et al. 1989; Bujo, H., Lindstedt, K.A. et 
al. 1995). The larger somatic cell variant LR8+ is likely to perform similar functions in 
mammals and oviparous species, as this isoform is expressed in the same tissues in these 
species. The tissue distribution may also simply suggest a role for the receptor in the 
transport and uptake of triglyceride-rich lipoproteins into metabolically active tissues 
(Hussain, M.M., Strickland, D.K. et al. 1999). 
 
Chicken LR8 shows high affinity binding of the major yolk precursors VTG via the lipovitellin 
domain (Stifani, S., Barber, D.L. et al. 1990) and VLDL via apolipoprotein B-100 (Nimpf, J,. 
Radosavljevic, M.J. et al. 1989). In doing so, the affinity of VTG for the oocyte receptor 
appears to be higher than for apoB. In addition, LR8 was shown to interact with RAP, a 
molecular chaperone for members of the LDLR family (see chapter 1.4.1.4).  
In 1990 Steyrer et al. showed that apolipoprotein E is an additional ligand for LR8. This is 
surprising and interesting, as apoE is an apolipoprotein of mammalian origin, which is absent 
in avian species (Steyrer, E., Barber D. L. et al. 1990). Since LR8 transports VTG in addition to 
VLDL, it has been suggested that VTG may represent a functional analogue of apoE. Its 
biochemical properties, the presence of regions with sequence homology to apoE and, most 
of all, binding to lipoprotein receptors that recognize apoE, strongly support this notion 
(Steyrer, E., Barber D. L. et al. 1990). According to the current knowledge, LR8 is 
hypothesized to be a product of ancient genes with the ability to interact with many, if not 
all, ligands of more recent members of the LDLR family.  
 
1.5.2 The chicken LDL Receptor 
Besides the massive transport of VLDL and VTG from the liver to the growing oocyte, there 
must be a way for somatic cells to independently control and maintain cholesterol 
homeostasis. In 1989, Hayashi et al. revealed that chicken fibroblasts express a different 
apoB- specific receptor than that identified in oocytes (Hayashi, K. Nimpf, J. et al. 1989). 
However, low levels of expression and sluggish regulation by sterols and statins were likely 
responsible for the delayed characterization of this receptor as bona-fide LDLR. Lately, 
Hummel et al. delineated this 130 kDa receptor as the first avian LDLR ortholog (Hummel, S., 
Lynn E. G. et al. 2003). It displays all hallmark properties of the LDLR family, which implicates 
that the overall structure of the LDLR has been conserved in evolution. Comparing the 
primary protein sequence between mammalian and chicken LDLR reveals only subtle 
differences: while the human LDLR contains a linker region with 12 residues in length 
between the LA repeat 4 and 5, this linker consists of 28 amino acids in the chicken LDLR. In 
addition, there are variations in the arrangement of negatively charged residues in the 
amino-terminal LA- repeat, in the sequence of the internalization signal, and also in the 
cytoplasmic receptor tail. LDL receptor protein expression was found to be restricted to 
adrenal glands, estrogen-induced liver, and somatic cells of the ovarian follicle. Unlike the 
function of the receptor in mammalian metabolism, in the laying hen the delivery of LDL- 
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derived cholesterol to tissues involved in steroid synthesis, such as adrenal and ovary 
appears to be particularly, or even exclusively, important. 
Ligand-binding studies demonstrated that the chicken LDLR binds to apoB-100 containing 
lipoproteins particles (VLDL, LDL), while the receptor adopts a preference of LDL over VLDL 
particles. This is consistent with its main role in providing lipoprotein-derived cholesterol for 
steroid production in somatic cells (Hummel, S., Lynn E. G. et al. 2003). In comparison to the 
chicken oocyte-specific receptor, and with mammalian LDLRs, the avian somatic LDLR cannot 
bind apoE or vitellogenin, thereby constituting the only known LDLR that interacts with apoB 
but not apoE (Bujo, H., Hermann, M. et al. 1997).  
 
 
 
1.6 AIMS OF THE THESIS 
In laying hens, the targeting of hepatically synthesized lipoproteins into oocytes and somatic 
tissues occurs simultaneously. This dual task is performed by efficient lipoprotein transport 
systems including receptors of the LDLR supergene family. The laying hen expresses two 
different apoB-specific receptors, of which the oocyte receptor LR8 is responsible for the 
massive uptake of yolk precursors from the plasma into the growing oocyte, and the somatic 
cell receptor (LDLR) is part of a regulatory system for maintenance of systemic cholesterol 
homeostasis.  
Although both avian receptors bind apoB-100- containing lipoproteins, LDL and VLDL, only 
the oocyte-specific receptor LR8 recognizes vitellogenin and the mammalian apoE. This 
indicates that in spite of the high homology between these two receptors, the ligand-binding 
domain of the ggLDL receptor seems to have a different structure that accounts for this 
unique binding property. The aim of this thesis is to reveal the structural determinants 
critical for the LDLR-apoE interaction and responsible for the differential ligand specificity of 
chicken LDLR and LR8.  
To elucidate these critical elements, I introduced a series of mutations in putatively 
important domains within the ligand-binding region of the chicken LDL receptor. The 
mutated receptors were further characterized regarding ligand-binding properties with the 
objective to reveal structural determinants important for apoE binding.  
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2. MATERIALS AND METHODS 
2.1 CHEMICALS AND REAGENTS 
Chemicals and general reagents commonly used in the experimental protocols of this thesis 
were obtained from:  Amersham Biosciences, Amresco, Applichem, Bio-Rad, Calbiochem, 
Fermentas, Fluka, Gerbu, Invitrogen, Merck, Pierce, Roche, Roth, Sigma Aldrich, Star Lab and 
Zymed. All restriction enzymes were purchased from Fermentas Life Sciences.  
 
2.2 BACTERIAL STRAINS AND VECTOR SYSTEMS 
Bacterial Strain XL10-Gold Ultracompetent Cells 
Genotype TetR Δ(mcrA)183 Δ(mcrCB-hsdSMR-mrr)173 
endA1 supE44 thi-1 recA1 gyrA96 relA1 lac Hte 
[F´ proAB lacIqZΔM15 Tn10 (TetR) Amy CamR] 
Reference Stratagene 
Table 2.1 Properties of E.coli XL10-Gold 
 
Bacterial Strain One Shot BL21 Star(DE3) Chemically 
Competent Cells 
Genotype F- ompT hsdSB (rB-mB-) gal dcm rne131 (DE3) 
Reference Invitrogen 
Table 2.2 Properties of E.coli BL21 
 
The commercial plasmid pMalc2x (New England Biolabs) was modified as described by 
Ronacher, B., Marlovits, T.C. et al. (2000) by the introduction of a novel multiple cloning site 
and a hexa- histidine tag provided at the C- terminal end of the resulting fusion protein.   
 
Vector pMalc2b 
Size 6710 basepairs 
Genotype lacI promoter, lacI coding sequence  
Multiple Cloning sites (NcoI- HindIII), His-
Tag, MBP-Tag, M13 origin, pBR origin, 
ampicillin resistance 
Reference pMalc2 from New England Biolabs 
Table 2.3 Properties of pMalc2b expression vector 
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2.3 PRIMERS 
The designed oligonucleotides were synthesized by MWG-Biotech AG. 
 
Name Sequence 
LA7m_fwd 5' -GAC GGC AGC GAT GAG TCG CCC GAA ATG TGC CGC- 3' 
LA7m_rev 5' -GCG GCA CTC CGT GCC GCC ATC GCA GAC CC- 3' 
LA7m5_fwd 5’ -GAT GGG TCC GAC GAG GAA GGA TGC GAC CCC CCC- 3’ 
LA7m5-rev 5’ -GGG GGG GTC GCA TCC TTC CTC GTC GGA CCC ATC- 3’ 
LA7del_fwd 5’ -GAA CGG AGC CCG ACG TGC GGG GTC GTC CCC CGG CCC- 3’ 
LA7del_rev 5’ -GGG CCG GGG GAC GAC CCC GCA CGT CGG GCT CCG TTC- 3’ 
Table 2.4 Primers used for site-directed mutagenesis 
2.4 ANIMALS 
Mature Derco brown laying hens (30-40 weeks old) were purchased from Heindl Co. (Vienna, 
Austria) and maintained on layer’s mash with free access to water and feed under a daily 
light period of 16 hours. For estrogen treatment, a rooster was injected with 17β-OH 
estradiol (10 mg/kg body weight) into the breast muscle. The liver was taken from the 
estrogenized rooster 48 h after injection.  
 
2.5 ANTIBODIES 
Protein Antibody Dilution 
ggLR8 Rabbit anti-LR8 antibody Conc. 10 µg/µl 
ggLDLR Rabbit anti-LA1-7 antibody 1: 1000 
ggLDLR-LA1-7-His Mouse anti-His antibody 1: 2000 
hsLDLR Rabbit anti-hLDLR2 antibody 1: 1000 
ApoE Mouse anti-ApoE antibody 1: 5000 
His-RAP-myc Mouse anti-myc antibody 1: 100 
ggApoB Rabbit anti-ggApoB antibody 1: 1000 
Rabbit IgG Goat anti-rabbit IgG 1: 50 000 
Mouse IgG Goat anti-mouse IgG 1: 1500 
Table 2.5 Antibodies 
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2.6 CELL CULTURE  
2.6.1 Cell lines 
Chinese hamster ovary cells (CHOwt, CHOApoE2, CHOApoE3, CHOApoE4) 
The CHO cell line is originally derived from the ovary of the Chinese hamster. Recombinant 
cell lines were produced as described in (Tagalakis, A.D., Graham, I.R. et al. 2001) and were a 
kind gift of Prof. Nimpf’s lab. CHO cells lacking the dihydrofolate reductase (DHFR) gene were 
stably transfected with apoE expression plasmids (p7055.apoE2/3/4) encoding the selectable 
DHFR gene  
Cell monolayers were cultured in Iscove’s MEM supplemented with 5% dialysed FCS, 2mM L-
glutamine, 1% non-essential amino acids, and 100 U penicillin and 100 µg streptomycin per 
ml. Cells were incubated in a 37°C incubator in an atmosphere of 7,5% Co2 in air.  
 
Mouse fibroblast cell line M4 ∆806 
The simian virus 40 large-T-antigen- immortalized mouse fibroblasts (M4 cell line) used in 
this study were kindly provided by Prof. D. Blaas. The cell line M4 ∆806 originates from 
murine wild-type fibroblasts featuring disruptions in genes coding for the LDL-receptor and 
LRP, though expressing a truncated form of the human LDL receptor, where a stop codon 
was introduced at amino acid 807 to disrupt the receptor internalization signal. M4 cells 
were maintained in Dulbecco’s modified essential medium (DMEM) supplemented with 5 % 
FCS, 2mM L- glutamine and 100 U penicillin and 100 µg streptomycin per ml. Cells were 
incubated in a 37°C incubator in an atmosphere of 7,5% CO2 in air.  
 
2.6.2 Solutions, Media and Supplements 
PBS (1x) 
137mM NaCl 
0.27 mM KCl 
10 mM Na2HPO4 
1.7 mM KH2PO4 
 
DMEM- Dulbecco’s modified essential medium (Invitrogen) 
IMDM- Iscove’s Modified Dulbecco’s Medium (Invitrogen) 
Opti-MEM- Reduced Serum Medium with GlutaMAX (Invitrogen) 
 
Supplements: 
L-Glutamine (100x; Invitrogen) 
FCS (Fetal Calf Serum) (Invitrogen) 
Penicillin/Streptomycin (100x; Invitrogen) 
Trypsin/EDTA solution (Invitrogen) 
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2.6.3 Growth of Cells 
Cells were grown as monolayers in tissue culture-treated dishes (IWAKI; 100 mm). All 
solutions added to cell cultures were pre-warmed to 37°C. Cellular growth and viability were 
supervised by phase contrast microscopy. After growing to subconfluency, cells were 
harvested from the culture dish by trypsin treatment: Cell monolayers were washed two 
times with PBS, trypsinized with 1 ml trypsin/EDTA solution and incubated at 37°C for 
several minutes. After detachment of the cells, the trypsin was neutralized with an 
appropriate amount of growth medium and the cells were splitted to fresh culture dishes in 
adequate dilution. All operations were performed under sterile conditions in a biohazard 
hood.  
 
2.6.4 Freezing and Thawing of Cells 
Freezing cells 
After washing two times with PBS cells were harvested by the addition of trypsin solution 
and the trypsinized cells were diluted in ~ 5 ml culture medium. The cell suspension was 
pelleted by centrifugation at RT for 3 min at 300 x g and the pellet was cryopreserved by 
resupending the cell pellet with 10% DMSO in FCS. The cells were transferred to cryo tubes 
(Nunc) and immediately cooled to -80°C for at least 5 days and for long term storage the vial 
was transferred to liquid nitrogen (-196°C).  
 
Thawing cells 
Frozen cells were thawed quickly by incubation in a 37°C water bath. To deplete the 
cryoprotecting agent dimethyl sulfoxid (DMSO) cells were washed with 10 ml culture 
medium and pelleted by centrifugation at RT for 3 min at 300 x g. The pellet was then 
resuspended in 1 ml medium and the cells were seeded in a fresh 100 mm culture dish 
containing 9 ml supplemented growth medium.  
 
2.6.5 Harvesting of ApoE- containing Lipoprotein Particles secreted from CHO Cells 
CHO cells secreting human apolipoprotein E isoforms (apoE2, apoE3, apoE4) were used to 
obtain human apolipoprotein E- containing lipoprotein particles. For harvesting 
apolipoprotein E isoforms, the CHO cells were cultured in 150 mm dishes until a confluency 
of 80% and then the growth media was switched to harvesting media (OptiMEM, 
Invitrogen). Collections were performed after a 12 h conditioning period and the isoform 
conditioned media were concentrated using Amicon- Ultra concentration columns with a 
30.000 kDa molecular weight cut off. ApoE isoforms were stored at 4°C.  
 
2.6.6 Quantification of ApoE by Enzyme-linked Immunosorbent Assay (ELISA) 
The concentrations of the apoE2, E3, E4 isoforms were measured by a sandwich ELISA 
(ApoE4/Pan-ApoE ELISA kit, MBL). The assay procedure was carried out at room 
temperature. Media samples from CHOapoE2, CHOapoE3 and CHOapoE4 were diluted 1:100 in 
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assay buffer and incubated for 1 h in provided microwell strips coated with polyclonal 
antibodies against human apoE. After washing 4 times with 100 µl wash solution, a 
peroxidise-conjugated anti-apoE antibody diluted 1:100 in conjugate diluent was added and 
incubated for 1 h. After another washing step, 100 µl peroxidase substrate (TMB/H2O2) were 
added and incubated for 30 min until the enzyme reaction was stopped by adding 50 µl stop 
solution (0.5 mol/l H2SO4). The optical density of each well was then measured at 450 nm 
using a microplate reader.  
A reference calibrator provided from the manufacturer was used to construct a standard 
curve to which the values of the samples were compared and calibrated.  
 
2.6.7 Solubilization of M4 ∆806 Cells and Preparation of Total Protein Extracts 
Cell monolayers were washed three times with ice cold PBS, harvested with a cell scraper, 
resuspended in 10 ml PBS and centrifuged at 2000 x g for 5 min (Haraeus Megafuge). Then 
the cell pellet was solubilized by the addition of buffer B (400 µl /150 mm dish). Insoluble 
material was removed by ultracentrifugation at 300.000 x g (Beckman TLA 100.1 rotor) for 
40 min at 4°C. Protein concentration of the total protein extracts were determined using the 
Bradford method and the cell extracts were quickly frozen in liquid N2 and stored at -80°C 
until use.  
 
Buffer B 
200 mM Tris/maleate, pH 6.5 
2 mM CaCI2 
1.4% Triton X-100 
Complete protease inhibitor cocktail (Roche) 
 
2.7 MOLECULAR BIOLOGICAL METHODS: DNA 
2.7.1 Site-directed Mutagenesis of Recombinant Plasmid DNA 
Mutant strand synthesis 
Mutations were introduced using QuikChange II XL Kit (Stratagene), which is an efficient 
polymerase chain reaction (PCR)- based site-directed mutagenesis method. This procedure 
employs a double-stranded DNA vector with an insert of interest and two synthetic 
oligonucleotide primers, both containing the desired mutation. A high-fidelity DNA 
polymerase catalyzes the extension of the mutagenic primers without primer displacement 
generating mutated plasmids. Following amplification the PCR- product is treated with Dpn I 
endonuclease triggering the digestion of the parental non-mutated DNA template, thereby 
selecting for mutation-containing DNA.  
The chicken ligand-binding domain (ggLA1-7) has been previously cloned by Bajari et al. 
(Bajari, T.M., Strasser, V. et al. 2005). The vector containing the recombinant receptor 
fragment was used as a template for the amplification reaction. Complementary mutagenic 
primers were designed according to the manufacturer’s instructions and are listed in table 
2.4.  
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The reaction mixture was prepared in a sterile PCR-tube as stated below and kept on ice: 
 
5 µl of 10x reaction buffer 
x µl (10 ng) of ds DNA template 
x µl (125 ng) of forward primer 
x µl (125 ng) of reverse primer 
1 µl of dNTP mix 
3 µl of QuikSolution reagent 
µl ddH2O to a final volume of 50 µl 
 
This mixture was subjected to thermal cycling in a Thermocycler T3000 (Biometra) using the 
stated PCR program.  
 
 Cycles Temperature  Time 
Initial Denaturation 1 95°C 1 minute 
Denaturation 
18 
95°C 50 seconds 
Annealing 60°C 50 seconds 
Extension 68°C 8 minutes 
Final Extension 1 68°C 7 minutes 
Table 2.6 Program used for site-directed mutagenesis 
 
Dpn I Digestion of amplification products 
The PCR- products were then digested for 1 h at 37°C by the addition of 1 µl of the Dpn I 
restriction enzyme (10U/µl).  
 
Transformation of XL10-Gold ultracompetent cells 
For transformation an aliquot (45 µl/reaction) was gently thawed on ice and mixed with 2 µl 
of β- mercaptoethanole. The cells were incubated on ice with gently mixing every 2 min. 
Then 2 µl of the Dpn I- treated DNA were transferred to the pre-treated ultracompetent cells 
and the reactions were incubated on ice for 30 min. The competent cells were heat shocked 
for 30 sec at 42°C and immediately chilled on ice for 2 min. The transformation mixture was 
diluted with pre-heated (42°C) S.O.C. medium and incubated for 1 h at 37°C with shaking at 
225-250 rpm. The transformed bacteria were plated on LB- ampicillin agar plates and grown 
o/n at 37°C.  
Single ampicillin-resistant colonies were picked and inoculated in 5 ml LB medium 
supplemented with 100 µg/ml ampicillin and grown o/n at 37°C. Plasmid DNA was isolated 
using the Fast Plasmid Mini Kit (Eppendorf).  
 
LB medium 
10g tryptone 
5g yeast extract 
10g NaCl 
ddH2O ad 1000 ml 
 
LB-Amp agar plates (100 µg/ml ampicillin) 
10g Tryptone 
5g Yeast Extract 
10g NaCl 
15g Agar-Agar 
ddH2O ad 1000 ml 
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2.7.2 Mini-Preparation of Plasmid DNA 
To extract and purify plasmid DNA from bacteria the FastPlasmid Mini kit from Eppendorf 
was used. The kit employs a rapid, non-organic alkaline lysis method using a single solution 
for cell resuspension, lysis, and DNA binding.  
The Complete Lysis Solution has been stored at 4°C prior to use. The procedure was 
performed at room temperature using a 5418 Eppendorf table centrifuge.  
1.5 ml overnight culture was harvested by centrifugation at 13.000 rpm for 1 min. The 
bacterial pellet was resuspended in 400 µl of ice-cold Complete Lysis Solution and mixed 
thoroughly by constant vortexing at the highest setting (30 sec). The lysate was allowed to 
incubate a RT for 3 min. Afterwards the lysate was transferred to Spin Column Assembly and 
centrifuged for 1 min at 13.000 rpm. Bound DNA was washed by adding 400 µl diluted Wash 
Buffer and the column was again centrifuged 1 min at 13.000 rpm. The filtrate was discarded 
and the Spin Column was placed back into the waste tube and centrifuged once again in 
order to dry the Spin Column. The Spin Column was transferred into a provided Collection 
Tube and 50 µl Elution buffer was added directly to the center of the Spin Column 
membrane. To elute Plasmid DNA another centrifugation step for 1 min at 13.000 rpm was 
done. The eluted DNA was used immediately for downstream applications or stored at -
20°C.  
 
2.7.3 Midi-Preparation of Plasmid DNA 
For the preparation of large scale plasmid DNA the QIAfilter Plasmid Midi Kit (QIAGEN) was 
used. All centrifugation steps were performed in Sorvall GSA- and HB-6 rotors. Picking a 
single colony a starter culture of 3 ml LB medium (100 µg/ml ampicillin) was inoculated and 
incubated approximately 8 h at 37°C under vigorous shaking. 500 µl of the starter culture 
were diluted in 100 ml fresh selective LB medium and growth was allowed o/n at 37°C under 
vigorous shaking. The bacterial culture was harvested by centrifugation at 6.000 x g for 15 
min at 4°C. After removing the supernatant, the cell pellet was resuspended and vortexed in 
5 ml buffer P1 until the pellet was completely dissolved. After the addition of 5ml Lysis 
buffer P2 the components were mixed by gently inverting 4-6 times and incubated at RT for 
5 min. Proteins and chromosomal DNA were precipitated by adding 5 ml ice-cold buffer P3 
and gently inverting 4-6 times. Then the cell lysate was poured into the barrel of a QIAfilter 
Cartridge and incubated at RT for 10 min. During the incubation a QIAgen-tip 100 column 
was equilibrated by applying 5 ml of buffer QBT. The lysate was cleared by filtration through 
the QIAfilter Cartridge and transferred to the pre-equilibrated binding column. The lysate 
was allowed to enter the resin by gravity flow. After washing the column two times with 10 
ml buffer QC, the DNA was eluted with 5ml buffer QF in a sterile 15 ml Falcon tube. To 
precipitate the DNA, the eluate was mixed with 3.5 ml isopropanol and centrifuged 
immediately at 15.000 × g for 30 min at 4°C. The DNA pellet was washed with 2 ml of 70% 
ethanol, air-dried and re-dissolved in an appropriate amount of sterile ddH2O. DNA 
concentration was determined with the NanoDrop Spectrophotometer ND-1000 (PeqLab) by 
measuring the absorption at 260 nm.  
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Buffer P1 (Resuspension buffer) 
50 mM Tris-HCl, pH 8.0 
10 mM EDTA 
100 μg/ml RNase A 
 
Buffer P2 (Lysis buffer) 
200 mM NaOH 
1% SDS (w/v) 
 
Buffer P3 (Neutralization buffer) 
3.0 M Potassium Acetate, pH 5.5 
 
Buffer QBT (Equilibration buffer) 
750 mM NaCl 
50 mM MOPS, pH 7.0 
15% Isopropanol (v/v) 
0.15% Triton X-100 (v/v) 
Buffer QC (Wash buffer) 
1 M NaCl 
50 mM MOPS, pH 7.0 
15% Isopropanol (v/v) 
 
Buffer QF (Elution buffer) 
1,25 M NaCl 
50 mM Tris-HCl, pH 8.5 
15% Isopropanol (v/v) 
 
TE-buffer 
10 mM Tris-HCl, pH 7.5 
1 mM EDTA 
 
 
 
 
2.7.4 DNA-Sequencing 
In order to confirm the efficiency and accuracy of site-directed mutagenesis the recombinant 
plasmid DNAs were subjected to sequencing conducted by VBC- Genomics Bioscience 
Research GmbH, Vienna, Austria.  
 
2.7.5 Transformation into Competent E. coli Cells 
Plasmids were transformed into chemically competent E. coli BL21 cells for high-level 
protein expression. Transformation of recombinant plasmids derived from Plasmid 
Preparation was done using the following protocol: An aliquot (50 µl/tube) of chemically 
competent E. coli BL21 cells was thawed on ice and mixed carefully with 5 µl plasmid 
minipreparation diluted 1:50. After an incubation of 30 min on ice, the bacterial cells were 
heat shocked for 30 sec at 42°C and immediately placed on ice again. For regeneration, 250 
µl of provided pre-warmed S.O.C. medium was added and the vial was incubated at 37°C for 
1 h under gentle agitation. 50 µl and 100 µl of the transformation mix were plated onto pre-
warmed selective LB-agar plates containing 100 µg/ml ampicillin and incubated at 37°C 
overnight. The transformants were screened for the insert-containing vector by restriction 
analysis and agarose gel electrophoresis.  
 
2.7.6 Restriction Enzyme Digestion 
For restriction analysis of recombinant plasmids derived by Plasmid preparation the 
following components were mixed and incubated for 1 h at 37°C: 
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3 µl   miniprep DNA 
5 units  appropriate restriction enzymes (EcoRI, XbaI (10 U/µl)) 
1 µl   appropriate 10x restriction buffer 
x µl  ddH2O to a final volume of 10 µl 
 
 
The appropriate restriction buffer was chosen according to recommendations of the 
manufacturer. The restriction digest was checked by agarose gel electrophoresis.  
 
2.7.7 Agarose Gel Electrophoresis 
Restricted plasmid DNA was analyzed by agarose gel electrophoresis using 1% (w/v) agarose 
gels containing 1 µg ethidium bromide per ml of gel. The DNA fragments were separated 
with a constant voltage of 100 V for 30 min. DNA samples were mixed with 5x DNA loading 
buffer and loaded onto the gel together with 8 µl of Generuler DNA Ladder Mix (Fermentas) 
serving as a size marker. 1x TAE buffer was used as electrophoresis running buffer.  
To visualize size-fractionated DNA molecules the agarose gel was illuminated with UV- light.  
 
50x TAE Buffer 
2 M Tris-HCl, pH 8.0 
1 M Acetic acid 
0.1 M EDTA 
 
5x DNA loading buffer 
5 ml 100% Glycerin 
2 ml 0.5 M EDTA 
12 ml 50x TAE 
3 ml ddH2O 
Bromphenol blue 
 
Ethidium bromide stock solution 
10 mg/ml in ddH2O 
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2.8 MOLECULAR BIOCHEMICAL METHODS: PROTEIN 
2.8.1 Preparation of Total Protein Extracts 
All operations were performed at 4°C. For total protein extracts, chicken tissues (either fresh 
or frozen at -80°C) were transferred to ice-cold homogenization buffer (4 ml/g wet tissue) 
and homogenized with an Ultra-Turrax T25 homogenizer 3 times for 20 sec. The 
homogenates were centrifuged for 10 min at 620 x g, 4°C, and Triton X-100 was added to the 
supernatant to a final concentration of 1%. After incubation for 30 min on ice, the 
supernatant was obtained by centrifugation at 300.000 x g for 1h and stored at –80°C until 
use. Protein concentration was determined using the method of Bradford.  
 
Homogenization buffer 
20 mM HEPES, pH 7.4  
300 mM sucrose 
150 mM NaCl 
Complete protease inhibitor cocktail (Roche) 
 
2.8.2 Preparation of Membrane Protein Extracts 
For membrane protein extraction chicken tissues (small white follicles, estrogen-treated 
rooster liver) was placed in ice-cold buffer A (5 ml of buffer A/g wet tissue). The tissues were 
subjected to homogenization using an Ultra-Turrax T25 homogenizer (3x 20 sec). Cellular 
debris was removed by centrifugation at 5 000 x g for 5 min, 4°C in a SS34 rotor (Sorvall), and 
the resulting supernatant was poured over 4 layers of cheesecloth into a fresh tube. The 
filtrate was centrifuged at 100.000 x g for 1 h in a TLA 100.3 rotor (Beckmann). The 
accumulated supernatant was discarded and the membrane pellets were washed in 3 ml 
buffer A by aspiration through a 18- and a 22-gauge needle and re-sedimented by 
ultracentrifugation at 100.000 x g for 1 h, 4°C. Again the supernatant was discarded. In order 
to solubilize membrane proteins the pellets were resuspended in 1 ml of buffer B, flushing 
again through an 18-and a 22-gauge needle. Afterwards, reagents were added to adjust the 
suspension to a final volume of 2 ml containing the following components: First 80 µl 4 M 
NaCl (4% of the total volume) was added and the suspension was sonicated once for 30 sec 
using a Bandelin sonicator (Bandelin, Berlin, Germany). Then 520 µl ddH₂O (26% Vol.) and 
400 µl 10% Triton X-100 (10% Vol.) were added to the samples. Undissolved material was 
removed by centrifugation at 100.000 x g for 1 h, 4°C. The clear supernatant, designated 
membrane extract, was aliquoted, quickly frozen in liquid nitrogen and stored at -80 °C until 
use. Protein concentration was determined using the Bradford method. 
 
Buffer A 
20 mM Tris-HCI, pH 8.0 
2 mM-CaCl2 
150 mM-NaCl  
Complete protease inhibitor cocktail 
(Roche) 
 
Buffer B 
250 mM Tris-maleate pH 6.0 
2 mM CaCl2 
Complete protease inhibitor cocktail 
(Roche) 
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2.8.3 Preparation of Chicken Lipoproteins 
VLDL and LDL were purified by preparative density-gradient centrifugation. Blood of a 
rooster was collected in a tube containing EDTA with a final concentration 1 mg/ml and 
plasma was obtained by centrifugation 15 min. at 3.500 rpm at 4°C using a Haraeus table 
centrifuge. In order to isolate VLDL and LDL fractions the plasma was adjusted to a density of 
1.063 g/ml by the addition of solid KBr and subsequent ultracentrifugation at 50.000 rpm for 
24 h at 4°C. Lipoproteins were fractionated by use of a SW41 Ti rotor in a Beckman XL 70 
centrifuge. Chicken VLDL and LDL were recovered from the top, diluted with LDL-buffer and 
stored at 4°C until use. The collected fraction was analyzed for protein content via Bradford 
assay and the purity was evaluated by SDS-PAGE.  
 
2.8.4 Expression and Purification of Recombinant Proteins 
The chicken ligand-binding domain (ggLA1-7) has been previously cloned by Bajari et al. 
(Bajari, T.M., Strasser, V. et al. 2005). A pMal expression vector provides the recombinant 
receptor fragments with a C-terminal His and an N-terminal maltose-binding protein (MBP)-
tag. Glycerol stocks of E. coli transformed with the expression vector pMalc2b harbouring 
the wt and mutated ggLA1-7s were used to prepare starter cultures of 3 ml LB medium (100 
µg/ml amicillin), which were incubated o/n at 37°C with vigorous shaking. These overnight 
cultures were diluted in 500 ml of LB medium supplemented with ampicillin (100 µg/ml). The 
cultures were grown under gentle shaking until the optical density (OD600) was 0.6. Then 
protein expression was induced by adding isopropyl ß-thiogalactopyranoside (IPTG) with a 
final concentration of 1 mM.  The expression was continued for 3-4 h at 37°C under gentle 
agitation (145 rpm) and the cells were pelleted by centrifugation for 15 min at 4°C and 5000 
rpm in a Sorvall centrifuge using a GS3 rotor. The cell pellet was resuspended in 6 ml lysis 
buffer and to achieve complete cell lysis, the cell suspension was sonicated 8 times for 30 
sec. on ice. The lysates were centrifuged at 4°C at 4000 rpm for 15 min using a Haraeus table 
centrifuge. The supernatant was collected and stored at -20°C or was used immediately. 
The recombinant His fusion proteins were purified by Ni–NTA affinity chromatography using 
the batch procedure according to the manufacturer’s instructions (Qiagen). 1 ml Ni-NTA 
sepharose beads, previously washed in lysis buffer, were added to 6 ml lysate and filled up 
with lysis buffer to a volume of 50 ml. This lysate-Ni-NTA mixture was allowed to incubate 
o/n on a rotary shaker at 4°C. The beads were harvested by centrifugation for 4 min. at 2000 
rpm and 4°C (Haraeus Megafuge). To remove unbound proteins the Ni-NTA beads were 
washed 4 times with 10 bed volumes of wash buffer (10 ml) and after each washing step the 
beads were harvested by centrifugation for 4 min. at 2000 rpm and 4°C.  
To achieve the dissociation of the His-tagged proteins from the Ni-NTA resin buffers 
increased imidazole concentrations were used. All in all, 3 elution steps were performed by 
adding 1 ml elution buffer and rotating the beads for 4 min at 4°C on a shaker at the highest 
setting. The beads were again centrifuged to collect the fractions with the purified proteins 
in the supernatant. The elutions were pooled and dialyzed o/n against 0.5 l buffer F using 
SnakeSkin Pleated dialysis tubes with a MWCO of 7.000 kDa (Thermo Scientific). Samples 
were either subjected immediately to re-folding procedures or stored at -80°C until use.  
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Lysis buffer  
50 mM Tris, pH 8.0 
500 mM NaCl 
1% Triton X-100 
0,1% Tween 20 
10% glycerol 
20 mM imidazol 
Complete protease inhibitor cocktail 
(Roche) 
 
Wash buffer 
50 mM Tris, pH8.0 
500 mM NaCl 
1% Triton X-100 
0,1% Tween 20 
30 mM imidazol 
10% glycerol 
Elution buffer  
50 mM Tris, pH 8.0 
500 mM NaCl 
1% Triton X-100 
0,1% Tween 20 
10% glycerol 
250 mM imidazol 
Complete protease inhibitor cocktail 
(Roche) 
 
Buffer F 
50 mM Tris-HCl, pH 7.4 
50 mM NaCl 
0.1 % Tween 20 
2 mM CaCl2 
 
 
2.8.5 Folding of Purified Proteins via RAP-Sepharose 
Expression of recombinant His-RAP-myc 
Rat RAP (receptor-associated protein) was subcloned into the expression vector pET-15b as 
described in (Bajari, T.M., Strasser, V. et al. 2005). The vector was transformed in E. coli BL21 
cells featuring a C-terminal His- and a N-terminal myc-tag. A small amount of an E. coli 
glycerol stock was inoculated in 5 ml LB-medium (100 µg/ml ampicillin) and incubated 
overnight at 37°C under vigorous shaking. The overnight culture was diluted with 1l pre-
warmed LB-medium (100 µg/ml ampicillin) and grown at 37°C until an optical density (OD600) 
of 0.6. The expression of His-RAP-myc was induced by the adding isopropyl β-thio-
galactopyranoside (IPTG) to a final concentration of 1 mM and shaking for 3 h at 37°C. The 
induced bacteria were harvested by centrifugation at 4000 x g for 10 min, resuspended in 2-
5 ml/g wet weight of lysis buffer and sonicated on ice (8x 10sec). The lysate was centrifuged 
at 10.000 x g for 45 min at 4°C and the supernatant was used for the purification of His-RAP-
myc by Ni-NTA affinity chromatography (see 2.8.4).   
 
Preparation of RAP- Sepharose 
To generate RAP-Sepharose the purified His-RAP-myc fusion protein was immobilized on 
CNBr- activated Sepharose 4B (Amersham Pharmacia Biotech). 1 g freezed-dried powder was 
supended in 30 ml 1 mM HCl and shaken on a rotary shaker for at least 30 min. at RT. The 
medium swelled immediately and resulted in about 3.5 ml final volume. To remove 
additives, the beads were washed on a glass filter funnel with 100 ml 1 mM HCl, added in 
several aliquots. In order to activate the sepharose the beads were rinsed with 20 ml of 
coupling buffer and the activated beads were incubated in the ligand to be coupled: 20 mg 
purified RAP fusion protein were dissolved in 20 ml coupling buffer containing protease 
inhibitors (Roche). The mixture was rotated gently o/n at 4°C on an end-over-end shaker. 
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Using the glass filter funnel excess ligand was sucked out and washed with a total of 150 ml 
coupling buffer. For blocking remaining active groups the beads were resuspended in 30 ml 
blocking buffer and rotated for 2-3 h at RT. Finally the sepharose was washed as described 
above with at least three cycles of alternating pH: 2 times with 50 ml wash buffer 1, 2 times 
with 50 ml wash buffer 2 and finally 4 times in alternating order. Until usage the coupled 
RAP- sepharose was stored in storage buffer at 4°C.  
 
Coupling buffer pH 8.3 
0.1 M NaHCO3 
0.5 M NaCl 
 
Blocking buffer pH 8.3 
1 M ethanolamine 
 
Wash buffer 1 pH 8.0 
0.1M boric acid 
1 M NaCl 
Wash buffer 2 pH 4.0 
0.1 M sodium acetate  
1 M NaCl  
 
Storage buffer pH 7.4 
25 mM Tris-HCl 
0.01% EDTA 
0.02% NaN3 
 
 
 
Refolding of ggLA1-7 receptor fragments via RAP-coupled Sepharose 
Purified, dialyzed ggLA1-7 receptor fragments were refolded by dialysis in the presence of 
500 µl of RAP-coupled sepharose with 2 mM reduced glutathione and 1 mM oxidized 
glutathione. After 72 h dialysis at 4°C against 1l buffer F, the glutathione was gradually 
removed by replacing one-tent of the dialysis buffer volume with buffer F every 1.5 h until 
the whole buffer volume was exchanged. Finally the bound protein was eluted from the 
RAP-Sepharose with buffer G. The eluted proteins were immediately adjusted to a pH of 8.0 
using 0.1 M HCl and then dialyzed against buffer F for 24 h to remove Ammonia.  
The purity and folding of the purified gg-LA1-7 fragments was determined by subjecting the 
eluted protein fraction to SDS-PAGE on a 7.5% polyacrylamide gel under both reducing and 
non-reducing conditions.  
 
Buffer G 
25 mM Tris 
75 mM NaCl 
0.1 M NH4OH 
 
2.8.6 Determination of Protein Concentration via Bradford Protein Assay 
To determine total protein concentration a dye-binding assay, based on the Bradford 
method was used (BioRad). This assay uses the dye Coomassie Brilliant Blue G-250, which 
binds selectively to basic and aromatic residues within peptides and proteins, and this 
binding is accompanied by a shift in absorbance maximum from 465 nm to 595 nm. The shift 
can be followed in a spectrophotometer by measuring the absorbance at 595 nm.   
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1 µl sample was mixed with 1 ml Bradford reagent, incubated for 5 min at RT and analyzed 
with a spectrophotometer at 595nm.  
A provided BSA standard with a given concentration (2mg/ml) was used to create a dilution 
series and the Bradford values for the standards are then used to construct a standard curve 
to which the values of the samples were compared.  
 
2.8.7 SDS-Polyacrylamide Gel Electrophoresis (SDS- PAGE) 
Protein extracts and recombinant proteins were analyzed by one- dimensional SDS- 
Polyacrylamide Gel electrophoresis using 7.5% and 12 % polyacrylamide gels.  Since a 
denaturing, discontinuous SDS-PAGE was performed two separately polymerized layers of 
polyacrylamide were prepared. First the ingredients of the separating gel (table 2.7) were 
mixed, poured into cleaned gel units (BioRad Mini gel system) and overlaid with isopropanol. 
The gel was allowed to polymerize for at least 15 min. After completely removing the 
isopropanol, the stacking gel was prepared and poured onto the polymerized separating gel. 
The combs were inserted and polymerization took place at least 15 min. At last the comb 
was removed, the slots were rinsed with ddH2O and the gels were assembled to the 
electrophoresis chamber filled with 1x electrophoresis buffer. 
 
 
Ingredients (1 gel) Stacking gel (4%) Separating gel (7.5%) Separating gel (12%) 
ddH2O 1525 µl 2425 µl 1675 µl 
1.5 M Tris-HCl pH 8.8 ― 1250 µl 1250 µl 
0.5 M Tris-HCl pH 6.8 625 µl ― ― 
30% Polyacrylamide 325 µl 1250 µl 2325 µl 
10% SDS 25 µl 50 µl 50 µl 
10% APS 12.5 µl 25 µl 25 µl 
TEMED 2.5 µl 5 µl 5 µl 
Table 2.7 Ingredients of gels used for SDS-PAGE 
 
Protein samples were analyzed under reducing (by adding 25 mM Dithiotreitol) or under 
non-reducing conditions according to Laemmli. In case of reducing conditions the samples 
were incubated for 10 min at 95°C before loading onto the gel.  
The gel was run at first at 80 V until the samples have entered the stacking gel and then the 
electric current was increased to 180 V until the Bromphenol Blue dye front migrated from 
the bottom of the gel. 5 µl of PageRuler Plus Prestained Protein ladder (Fermentas) or 8 µl of 
Unstained Precision Plus Protein Standard (BioRad) were applied, serving as molecular 
weight markers.  
Following electrophoresis, the gels were either subjected to Coomassie blue staining or to 
Western- and Ligand blot analysis.   
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Acrylamide stock  
29.2% Acryamide 
0.8% N,N’-Methylenbisacrylamide 
 
4x Laemmli buffer 
31.2% Glycerine 
6% SDS 
20 mM Tris-HCl pH 7.4-7.5 
as reducing agent 25mM Dithiothreitol (DTT) was added 
 
1x Electrophoresis buffer 
25 mM Tris 
0.192 M Glycine 
1% SDS 
 
2.8.8 Coomassie Staining 
In order to stain proteins in SDS-PAGE gels, the polyacrylamide gel was soaked in Coomassie 
solution and incubated for at least 1 h at RT on a laboratory shaker. The gel is then destained 
for 2 h at RT or o/n at 4°C with frequent changes of destaining solution until the gel 
background is clear and protein bands could be clearly visualized. For the purpose of 
documentation the gels were dried in a gel vacuum dryer for 50 min at 80°C.  
 
Coomassie solution 
10% Acetic acid 
25% Isopropanol 
0.287 g Coomassie Brilliant Blue R250 in ddH2O 
 
Destaining solution 
10% Acetic acid 
30% Methanol in ddH2O 
 
2.8.9 Western Blot Analysis 
Wet- (Tank-) Blotting 
After electrophoresis the separated proteins were transferred to nitrocellulose membranes 
(Hybond-C Extra; Amersham Biosciences) using wet blotting Mini Trans-Blot System 
(BioRad). Before blotting the stacking gel was removed and the provided support pads of the 
transfer unit and the Whatman papers were soaked in 1x transfer buffer. The blot was 
assembled in the following order: support pad, 3 Whatman papers, gel, nitrocellulose 
membrane, 3 Whatman papers and again support pad. The sandwich was placed in the 
electrotransfer unit with the membrane side of the sandwich positioned at the positive 
terminal. The transfer was performed at a constant current of 100 V for 1 h under chilled 
conditions. Following transfer, the blotting efficiency was checked by staining the membrane 
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with Ponceau S. Immobilized proteins and standards were visualized by rinsing the 
membrane with ddH2O.   
 
Detection 
Signals were detected using the enhanced chemiluminescence (ECL) method (Pierce). This 
method depends on the incubation of the membrane with a substrate that produces 
luminescence when exposed to horseradish peroxidase (HRP)-conjugated to the secondary 
antibody.  
At first the membrane was blocked at least 1 h with 5% non-fat dry milk in 1x TBS-T buffer 
(blocking solution). After removing the blocking solution, the membrane was incubated o/n 
at 4°C or at least 1 h at RT with primary antibody (diluted in blocking solution). The 
membrane was washed 3x 10 min in 1x TBS-T, followed by incubation with a secondary HRP-
conjugated antibody (diluted in blocking solution). After 1 h incubation the membrane wash 
washed another 3 times for 10 min with 1x TBS-T. An equal amount of ECL solution 1 and 2 
were mixed, spread over the blot and incubated for 3 min. The excess of ECL solution was 
drained off, the membrane was placed in an X-ray cassette and exposed to an 
autoradiography film (Pierce, CL-XPosureTMFilm) depending on the intensity of the signal and 
background. 
 
 
1x Transferbuffer 
25 mM Tris 
192 mM Glycine 
 
1x PBS 
137 mM NaCl 
0.27 mM KCl 
10 mM Na2HPO4 
1.7 mM KH2PO4 
 
1x TBS-T 
25 mM Tris-HCl,  pH 7.4 
140 mM NaCl 
2.5 mM KCl 
0.1 % Tween 20 
 
Ponceau S 
1x PBS 
0.2% Ponceau S 
3% Trichloracetic Acid 
2.8.10 Ligand Blot Analysis 
Ligand blot analysis is a technique derived from the standard Western blot method to detect 
protein-protein interactions in vitro.  
Proteins were separated by SDS-PAGE and electrophoretically transferred to nitrocellulose 
membrane via wet-blotting according to the Western Blot protocol. Nonspecific binding sites 
on the membrane were blocked for 1 h at RT using 5% non-fat dry milk in 1x TBS-T + 2mM 
CaCl2 (blocking buffer). In case of testing multiple interacting partners the membrane was 
cut into single strips, each probing with different ligands. The indicated ligand proteins were 
diluted in blocking buffer and the formation of specific protein-protein interactions was 
allowed o/n at 4°C under gentle agitation.  
Unbound proteins were washed off 3 times for 20 min with 1x TBS-T+ 2 mM CaCl2. After 
washing a ligand-specific antibody was diluted in 1x TBS-T + 2mM CaCl2 and was added to 
the membrane. After 1h of incubation at RT under gentle agitation, the membrane was 
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washed another 3 times for 10 min with 1x TBS-T + 2 mM CaCl2. An appropriate HRP- 
conjugated secondary antibody diluted in blocking buffer was added and incubated for 1 h at 
RT. Finally the membrane was rinsed 3 times for 10 min with 1x TBS-T + 2 mM CaCl2 prior to 
chemiluminenescent detection using the ECL kit from Pierce.  
 
2.8.11 Co-Immunoprecipitation 
Co-Immunoprecipitation was carried out to precipitate protein complexes and to investigate 
protein- protein interactions. Receptor fragments (LA7wt, LA7m, LA7del, LA7dbl) obtained 
from the re-folding procedure were incubated with 15 µg bacterially expressed, purified His-
RAP-myc for at least 2 h or o/n on a rotator at 4°C under gentle agitation. Following this 
incubation, a monoclonal anti-myc antibody was added and the samples were incubated for 
2 hr at 4°C on a rotator under gentle agitation. After this incubation period, the Protein A 
Sepharose beads (50 µl wet volume) were added to the mixtures. Samples were incubated 
overnight at 4°C under gentle agitation as mentioned above. The next day, the samples were 
centrifuged for 2 min at 2000 rpm and 4°C. The supernatant was discarded and the beads 
were washed 3 times with 500 µl 1x TBST + 2 mM CaCl2 + proteinase inhibitor (ROCHE). In 
between the washing steps, the beads were centrifuged for 2 min. at 2000 rpm and 4°C to 
remove the supernatant. After the final centrifugation, the supernatant was discarded and 
an appropriate amount of 4x Laemmli buffer + 25mM DTT were added to the beads. 
Afterwards, samples were heated up to 95°C for 10 min to separate the proteins from the 
beads. Samples were centrifuged and the supernatant was analyzed by SDS-PAGE and 
Western blotting.  
 
2.8.12 ELISA- based Solid Phase Binding Assay 
ELISA was performed in 96 flat-bottom wells (Greiner). The wells were coated either with 
tissue membrane protein extracts or recombinant purified proteins diluted in 1x TBS + 2 mM 
CaCl2 (100 µl/well). The plate was incubated o/n at 4°C under gentle agitation and humid 
conditions to avoid the microtiter plate to run dry during incubation. After 2 washes with 
blocking solution, the wells were subsequently blocked for 1 h with 100 µl of blocking 
solution (2% (w/v) BSA in 1x TBS + 2 mM CaCl2). Then the wells were incubated for 1 h with 
100 µl of different concentrations of the respective ligands diluted in blocking buffer. The 
assay proceeded with 4 washing steps by adding and discarding 100 µl of blocking solution 
prior to 1 h incubation with the primary, ligand-specific antibody. Wells were again washed 4 
times with 2% BSA solution and supplied with 100 µl of appropriate HRP-conjugated 
secondary antibody diluted in blocking buffer. After a series of final washes with 1x TBS the 
peroxidase activity was measured by the addition of 100 µl 3,3′,5,5′-Tetramethylbenzidine 
(TMB; Sigma) as substrate solution. The reaction was stopped after 5-10 min by the addition 
of 50 µl of 1 M H2SO4. The enzyme activity was monitored by measurement of absorbance at 
450 nm using a microtiter plate reader.  
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3. RESULTS 
To gain better insights into the mechanism of apolipoprotein-receptor interactions and to 
reveal the critical structural requirements that are essential for interaction, this study was 
performed in the domesticated chicken (Gallus gallus), an established model organism for 
research on lipid metabolism in our research group. Avian and mammalian members of the 
LDL receptor family share characteristic similarities, both in structural and functional terms. 
This high degree of homology becomes apparent when the primary protein sequences of 
distinct family members are compared. Figure 3.1 depicts the alignment of the chicken LDLR, 
the chicken VLDLR, termed LR8, and the human LDLR.  
The overall receptor architecture is highly similar including typical hallmarks of this receptor 
family. In general, the ggLDLR and the humLDLR are composed of a ligand-binding domain 
consisting of 7 LA- repeats, followed by EGF-like repeats, an O-linked sugar domain, a 
transmembrane- as well as a cytoplasmic domain. The chicken VLDL receptor displays almost 
the same build-up, though harboring an extra N-terminal LA- repeat and lacking the O-linked 
sugar domain. Comparing the protein sequences of between the human and the chicken 
LDLR reveals some subtle differences. These include that the linker region between the sixth 
cysteine in LA repeat 4 and the first cysteine of LA repeat 5 consists of 12 residues in the 
human, but 28 residues in the chicken receptor. Moreover, the arrangement of negatively 
charged residues in the C- terminal region of LA repeats, particularly that of LA1 and LA5, 
and the intracellular domain harboring the internalization signal show some differences 
(Hummel, S., Lynn, E.G. et al. 2003).  
 
                                                                   
 chickenLR8    (1) MRSSRQRGDRSAATGGGCGARRWALPRCGALCLLLALGCLRTATDGAKAK (50) 
chickenLDLR    (1) MAAWALLLGVLLSAA----------------------------------- (15) 
  humanLDLR    (1) MGPWGWKLRWTVALLLAAAGT----------------------------- (21) 
                                                                 
 chickenLR8   (51) CEESQFQCSNGRCIPLLWKCDGDEDCSDGSDESACVKKTCAESDFVCNSG (100) 
chickenLDLR   (16) ----------------------------------TDVWGCDPEQFRCGDG (31) 
  humanLDLR   (22) ----------------------------------AVGDRCERNEFQCQDG (37) 
                                                                
 chickenLR8  (101) QCVPNRWQCDGDPDCEDGSDESAELCHMRTCRVNEISCGPQS--TQCIPV (148) 
chickenLDLR   (32) GCISATWVCDGGTECRDGSDEEPEMCRSLQCPAQHFDCGDAVGRERCVPL (81) 
  humanLDLR   (38) KCISYKWVCDGSAECQDGSDESQETCLSVTCKSGDFSCGGRV--NRCIPQ (85) 
                                                              
 chickenLR8  (149) SWKCDGEKDCDSGEDEENCGNVTCSAAEFTCSSGQCISKSFVCNGQDDCS (198) 
chickenLDLR   (82) SWRCDGHRDCRHGADEWGCEPPPCASDQQRCSDGSCVSRAFLCDGDRDCP (131) 
  humanLDLR   (86) FWRCDGQVDCDNGSDEQGCPPKTCSQDEFRCHDGKCISRQFVCDSDRDCL (135) 
                   
 chickenLR8  (199) DGSDELECAPPT-CGVHEFQCKSSTCIPISWVCDDDADCSDHSDESLEQC (247) 
chickenLDLR  (132) DGGDERDCPPPPPCPPASFRCPDGVCVDPAWLCDGDADCADGADERSPTC (181) 
  humanLDLR  (136) DGSDEASCPVLT-CGPASFQCNSSTCIPQLWACDNDPDCEDGSDEWPQRC (184) 
                                                                
 chickenLR8  (248) G-------------------RQPAPPVKCSTSEVQCGSGECIHKKWRCDG (278) 
chickenLDLR  (182) AEATAAEAEAAEAEAEEGEGVVPRPAQRCPPLRVPCRSGGCVPRGWRCDG (231) 
  humanLDLR  (185) RGL----------------YVFQGDSSPCSAFEFHCLSGECIHSSWRCDG (218) 
                                                                
 chickenLR8  (279) DPDCKDGSDEINCPSRTCRPDQFRCED-GNCIHGSRQCNGVRDCLDGTDE (327) 
chickenLDLR  (232) SPDCSDGSDEDGCDPPLCPPEEFRCADDGRCVWGGRRCDGHRDCADGSDE (281) 
  humanLDLR  (219) GPDCKDKSDEENCAVATCRPDEFQCSD-GNCIHGSRQCDREYDCKDMSDE (267) 
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 chickenLR8  (328) ANCNNVIQCSGPGKFKCRSGECIDINKVCNHHGDCKDWSDEPLKECNINE (377) 
chickenLDLR  (282) DGCDNAPSCVGPDVFQCRSGECIPTERLCDGRRHCRDWSDEPLQHCDVDE (331) 
  humanLDLR  (268) VGCVNVTLCEGPNKFKCHSGECITLDKVCNMARDCRDWSDEPIKECGTNE (317) 
                   
 chickenLR8  (378) CLVNNGGCSHICRDLVIGYECDCPAGFELVDR-RTCGDIDECQNPGICSQ (426) 
chickenLDLR  (332) CSQGTSGCSHGCQDRPIGFRCLCPDGFRLGADGKTCEDVDECAEAERCAQ (381) 
  humanLDLR  (318) CLDNNGGCSHVCNDLKIGYECLCPDGFQLVAQ-RRCEDIDECQDPDTCSQ (366) 
                   
 chickenLR8  (427) ICINLKGGYKCECSRGYQMDLATGVCKAVGKEPCLIFTNRRDIRKIG--- (473) 
chickenLDLR  (382) LCINLQGAFKCACAEGYAAEPGGRSCRALAPVSELLLWSRRTLRRVAGSA (431) 
  humanLDLR  (367) LCVNLEGGYKCQCEEGFQLDPHTKACKAVGSIAYLFFTNRHEVRKMT--- (413) 
                                                               
 chickenLR8  (474) LERK---EYIQLVEQLRNTVALDADIAEQKLYWADFSQKAIFSASIDTRD (520) 
chickenLDLR  (432) VGRAGLRSTQWLRGDFPHGAVADVDVAEGNLYWADPTQRRLFRAPLSPPG (481) 
  humanLDLR  (414) LDRS---EYTSLIPNLRNVVALDTEVASNRIYWSDLSQRMICSTQLDRAH (460) 
                                                                
 chickenLR8  (521) KVG-THTRILDNIHSPAGIAVDWIYKNIYWTDSSAKTISVASLNGKK--- (566) 
chickenLDLR  (482) APP---TPLQLLEGVPTALALDWVHHVLYWGDSTGGALRALPVGGSGGAL (528) 
  humanLDLR  (461) GVSSYDTVISRDIQAPDGLAVDWIHSNIYWTDSVLGTVSVADTKGVK--- (507) 
                                                                
 chickenLR8  (567) RKVLFLSELREPASIAVDPLSGFMYWSDWGEPAKIEKAGMNGFDRQQLVT (616) 
chickenLDLR  (529) SATIWQRNGSEPRGIALDPMLGLLFWSDCGSVPLLGRVGLNGAEPKVLLE (578) 
  humanLDLR  (508) RKTLFRENGSKPRAIVVDPVHGFMYWTDWGTPAKIKKGGLNGVDIYSLVT (557) 
                   
 chickenLR8  (617) TEIQWPNGIALDLVKSRLYWLDSKLHMLSSVDLNGQDRRLVLKSHMFLPH (666) 
chickenLDLR  (579) RGLRCPCGLALDVPSQRLYWADRQLHSLSSVSVWGGQRRTLLADPQLLPH (628) 
  humanLDLR  (558) ENIQWPNGITLDLLSGRLYWVDSKLHSISSIDVNGGNRKTILEDEKRLAH (607) 
                                                               
 chickenLR8  (667) PLALTIFEDRVFWIDGENEAVYGANKFTGAELVTLVNNLNDAQDIIVYHE (716) 
chickenLDLR  (629) PMAVTVFEDSVFWTDAQRGAVLSAPRRSEGEVRVVAESLPGVGGVLVVHP (678) 
  humanLDLR  (608) PFSLAVFEDKVFWTDIINEAIFSANRLTGSDVNLLAENLLSPEDMVLFHN (657) 
                                                                
 chickenLR8  (717) LVQPSGRNWCEEN-MVNGGCSYLCLPAPQINEHSPKYTCTCPAGYFLQED (765) 
chickenLDLR  (679) LRQPRGVNVCAPS---NGGCEGLCLPAPHTEPHSAPYSCVCGDGLRLEAD (725) 
  humanLDLR  (658) LTQPRGVNWCERTTLSNGGCQYLCLPAPQINPHSPKFTCACPDGMLLARD (707) 
                                                                
 chickenLR8  (766) GLRC---------------------------------------------- (769) 
chickenLDLR  (726) GRRCQPDPTAPTPMGPNSTTAAPQPHSTNGAHSTETHSNGAHSNGTHSTE (775) 
  humanLDLR  (708) MRSC---------LTEAEAAVATQETSTVRLKVSSTAVRTQHTTTRPVPD (748) 
                                                                 
 chickenLR8  (770) -------------------------GGFNISSVVS-EVAARGAAGAWAVL (793) 
chickenLDLR  (776) THSTNGAHSANGTHSNGTGSTALRSDAVGPPSVGPPSVGPPSVGPPSSVG (825) 
  humanLDLR  (749) TSRLPGATPGLTTVEIVTMSHQALGDVAG---RGN-EKKPSSVRALSIVL (794) 
                                                                
 chickenLR8  (794) P--ILLLVTAALAGYFMWRNWQHKNMKSMN---------FDNPVYLKTTE (832) 
chickenLDLR  (826) PQSGLVALAVLLPLALLGALWALRALRRWWRRRSSHSISFGNPLFLKEHG (875) 
  humanLDLR  (795) P--IVLLVFLCLGVFLLWKNWRLKNINSIN---------FDNPVYQKTTE (833) 
                                            
 chickenLR8  (833) EDLTIDIGRHSGSVGHTYPAISVVSTDDDML (863) 
chickenLDLR  (876) --------------GHQWQSLSGDSGDSGV- (891) 
  humanLDLR  (834) DEVHICHNQD----GYSYPSRQMVSLEDDVA (860) 
 
Figure 3.1 Protein sequence comparison of chicken LR8, chicken LDLR, and human LDLR  
Numbering of the amino acid sequences starts at the methionine residue corresponding to the 
initiation codon. Identical and conserved residues are shaded in dark-, similar residues in light grey.  
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3.1 MOLECULAR CHARACTERIZATION OF human LDLR-APOE INTERACTION 
Many previous and current studies are focusing on the ligand-binding properties of various 
members of the LDL receptor family. The LDL receptor is the best characterized member of 
this family, and the ligand recognition by this receptor has been studied extensively. The 
human LDLR achieves its physiological function by binding cholesterol-rich particles via 
apolipoprotein E and/or apolipoprotein B and thereby mediates their internalization and 
subsequent lysosomal degradation. Molecular characterization of the precise binding event 
revealed that the LDLR discriminates against distinct variants of apolipoproteins residing on 
lipoproteins. In mammals, apoB exists in 2 forms: as apoB-100 representing the full length 
protein and as apoB-48, a truncated form corresponding to the N-terminal 48% sequence of 
apoB-100. Multiple investigations showed that the LDLR is capable to bind only lipid particles 
harboring apoB-100. 
Furthermore, the second LDLR-ligand, apoE, was shown to exist in 3 isoforms, differing from 
each other by single amino acid substitutions. Several studies have provided evidence that 
the human LDLR displays a differential behavior in binding to the various apoE isoforms. 
While ApoE3 has the highest affinity for the receptor, apoE4 features a lower but modest 
affinity, whereas E2 displays only a weak binding capacity (Schneider, W.J., Kovanen, P.T.et 
al. 1981).  
 
Since apoE need to be associated with lipids to confer high receptor binding activity apoE- 
containing particles were harvested from CHO cell lines stably secreting the recombinant 
isoforms. The resulting apoE particles have been characterized by other research groups also 
conducting studies with apoE (Stannard, A.K., Riddell, D.R. et al. 2001). Separation by gel 
electrophoresis revealed that the the apoE2-, E3- and E4-containing lipid particles have pre-
α mobility similar to the majority of plasma HDL particles. Using non-denaturing gel 
electrophoresis, some differences between the isoforms can be denoted. As depicted in 
figure 3.2B, three main apoE particle populations were identified with hydrated diameters of 
7.6, 8.0 and 10.4 nm. The 8 nm particle was prominent in apoE3 media, less abundant in 
apoE2 media, and absent in apoE4 media. The other particles were present in all three 
isoforms (Sacre, S.M., Stannard, A.K. et al. 2003). This difference in particle population 
confirms the effect of the distinct protein isoforms on the lipid association properties 
resulting in differently sized particles. To control the presence of apoE molecules, the 
particles were treated with detergent, heated to 95°C und further subjected to SDS-PAGE 
and Western Blot analysis (figure 3.2A).  
The apolipoprotein E content of these particles was quantified by an ELISA kit and according 
to the obtained protein concentrations, the apoE particles were applied to several binding 
assays throughout this study. 
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Figure 3.2 Characterization of apoE particles 
A: ApoE particles secreted from CHOapoE2/3/4 were 
separated by SDS-PAGE on 12% polyacrylamide gels 
under reducing conditions and analyzed by Western 
blot analysis using specific α-apoE antibodies. Equal 
amounts   were used for each isoform quantified by 
enzyme-linked immunosorbent assay (ELISA). 
 
B: Particle diameters from apoE2, -E3, -E4 particles 
derived from CHO cells were assessed by non- 
denaturing gel electrophoresis (NDGE) and 
immunoblotted for apoE as described by Sacre, S.M., 
Stannard, A.K et al. (2003).  
  
 
Using a solid phase binding assay based on the principle of ELISAs, I investigated the binding 
characteristics of the LDL receptor to the apoE isoforms E2, E3 and E4. As a source of 
receptor, I cultivated mouse embryonic fibroblasts (M4 ∆806) expressing a truncated form of 
the human LDL receptor incapable of internalization, thus exhibiting an active ligand-binding 
domain. Total protein extracts were prepared, coated onto microtiter plates and incubated 
with increasing concentrations of apoE2-, E3- and E4-containing lipid particles. Using a 
monoclonal apoE antibody, it was possible to detect the amount of apoE captured on the 
plate through the specific interaction with the LDLR.   
Figure 3.3 Saturation curve for the binding of apoE isoforms to the human LDLR 
 A solid phase assay was used to measure the interaction of human LDLR with apoE isoforms. 
Indicated concentrations of apoE2-, E3- and E4- containing lipid particles were added to wells 
previously coated with 45 µg M4 ∆806 cell extract. Bound apoE was determined by using anti-apoE 
antibody and visualization was performed as described in materials and methods. High affinity 
binding was calculated by subtracting non-specific binding from total binding. Each data point 
represents the average of duplicate determinations.  
A 
B 
B 
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Figure 3.3 shows that apoE3 featured a high LDL receptor binding activity followed by apoE4, 
while the binding of apoE2-containing lipid particles was considerably lower. This pattern is 
in agreement with investigations by Weisgraber et al., where they reported a 50- to 100- 
times weaker binding potential for apoE2 (Weisgraber, K.H., Innerarity  T.L. et al. 1982) 
 
3.2 MOLECULAR CHARACTERIZATION OF ggLR8-APOE- INTERACTION  
Very low-density lipoprotein receptors (VLDLR) show a very high degree of conservation 
among different species. Within mammals, i.e. man, mouse, rat and rabbit, there is a 95% 
identity between the corresponding receptor proteins (reviewed by Nimpf,J. and Schneider, 
W.J. 1998). The chicken VLDL receptor LR8 shares about 84% identical residues with the 
human VLDL receptor (Bujo, Hermann et al. 1994). Thus, the identity between human and 
chicken VLDL receptors is much greater than that between LDL and VLDL receptors of the 
chicken.  
In contrast to the mammalian VLDLR, whose role in lipid metabolism is still not completely 
resolved, the function of LR8 in avian species is well established. It mediates a key step in the 
reproductive effort of the egg-laying hen. LR8 resides in the plasma membrane of the oocyte 
and is responsible for the deposition of the two yolk precursors vitellogenin and VLDL from 
the plasma into the growing oocyte. In addition, LR8 mediates the uptake of other transport 
proteins, such as transferrin, riboflavin-binding protein, retinol-binding protein, thiamin-
binding protein, certain biotin-binding proteins, cobalamin-binding protein, and 
cholecalciferol (Nimpf, J., George, R. et al. 1988).   
The receptor is specific for the apoB moiety of the VLDL particle, while apolipoprotein VLDL-
II, a lipoprotein lipase inhibitor also present on VLDL particles from laying hens, was shown 
not to be involved in receptor binding (Nimpf, J., George, R. et al. 1988). Moreover, 
apolipoprotein E, an apolipoprotein, which is not produced in birds, but is regarded as the 
mammalian counterpart of VTG, was identified as an additional ligand for LR8 (Steyrer, E., 
Barber, D.L. et al. 1990).   
Using the technique of direct ligand blot analysis, I investigated the binding properties 
between LR8 and the previously characterized apoE particles (figure 3.4). As a source of 
receptor I used membrane extracts of chicken ovarian follicles, which are enriched in the 
major oocyte receptor. After performing SDS-PAGE under non-reducing conditions, the 
nitrocellulose strips were incubated with apoE-containing particles. Following detection with 
specific apoE antibodies, receptor-ligand interactions could be detected for all three apoE 
isoforms (figure 3.4, lanes 3-5).  
To detect LR8 in the ovarian follicle membrane extracts, antibodies against LR8 were used 
and visualized LR8 as a protein with a molecular weight of 95 kDa. Additional bands 
emerging above the 95 kDa protein represent receptor dimers or multimers favored under 
non-reducing conditions. Furthermore, when the follicle extract had been subjected to SDS-
PAGE under reducing conditions by adding dithiotreitol as reducing agent, the binding of all 
three apoE isoforms was abolished. This demonstrates that the receptor binding activity of 
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LR8 for apoE requires the presence of intact disulfide bonds, as it is known for the 
interaction with LDL.  
 
 
Figure 3.4 ApoE isoforms bind to chicken oocyte receptor LR8  
A laying hen small white follicle membrane protein extract was prepared, and 25 μg extract per lane 
were subjected to non-reducing (-DTT, left) and reducing (+DTT, right) SDS-PAGE using a 7.5% PAA-
gel, and separated proteins were blotted to nitrocellulose membrane. After the blocking of unspecific 
binding sites, 1 µg apoE2-, E3- and E4- particles harvested from CHOapoE2/E3/E4 cells were added as 
ligands (lanes 3-5, 8-10). After washing, the bound apoE protein was detected using anti-apoE 
antibody. Anti-LR8 antibody (lanes 1, 6) was used to visualize LR8 in the ovarian follicle membrane 
extract. The bound primary antibodies were detected either with HRP-conjugated anti-rabbit IgG or 
HRP-conjugated anti-mouse IgG and visualized using the chemiluminescence detection method, as 
described in materials and methods. The positions of migration (kDa) of marker proteins are 
indicated. 
 
 
 
The ability of human apoE to bind to chicken LR8 was further characterized using the ELISA-
based solid phase binding assay. Microtiter plates were coated with follicle detergent 
extracts and incubated with the indicated concentrations of apoE-containing particles. 
Comparable to the human LDLR, apoE3 displayed the highest binding capacity to chicken 
LR8. In mammals, ApoE2 is characterized by a low binding activity towards apoE- receptors. 
Interestingly, in the chicken system apoE4, and not apoE2, showed the least binding to LR8, 
while apoE2 had a lower binding potential than apoE3, which nonetheless was significantly 
higher than that for mammalian receptors (figure 3.5).  
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Figure 3.5 Saturation curve for the binding of apoE to the chicken oocyte receptor 
Microtiter plates were coated with 25 µg small white follicle membrane extract, and after blocking 
with 2% BSA increasing concentrations of apoE2, E3 and E4 particles were added. Bound apoE was 
detected as described in materials and methods. High affinity binding was calculated by subtracting 
non-specific binding from total binding. Each data point represents the average of duplicate 
determinations. 
 
 
 
The Receptor- associated protein (RAP) is another ligand known to bind to all members of 
the LDL receptor family. Under physiological conditions RAP is found within the 
endoplasmatic reticulum and plays an important role in the early processing of receptors by 
preventing the premature association with ligands on the one hand, and regulating the 
receptor transport to the cell surface on the other hand (Bu, G., Geuze, H.J. et al. 1995).  
The potential of RAP to bind to the chicken VLDL receptor was evaluated by ligand blot 
analysis and is depicted in figure 3.6. Lane 8 represents the binding of His-RAP-myc to LR8 
under non- reducing conditions. Lanes 2-4 show that His-RAP-myc very efficiently competes 
with all apoE isoforms for the binding sites on LR8. The addition of RAP as ligand completely 
abrogates the interaction of apoE2, E3 and E4. On the contrary, the binding of RAP itself was 
not altered by the presence of apoE (lane 5 apoE2, lane 6 apoE3, lane 7 apoE4), which 
demonstrates that RAP is a receptor ligand with very high affinity for LR8. Nevertheless, 
binding of RAP to LR8 was impaired when the binding analysis was performed under 
reducing conditions (data not shown).  
ggLR8 - ApoE 
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Figure 3.6 Receptor-associated protein (RAP) competes with apoE for receptor binding sites 
25 µg small white follicle detergent extract per lane were subjected to SDS-PAGE under non-reducing 
conditions using 7.5% PAA-gels. Separated proteins were blotted to nitrocellulose and incubated 
with 1 µg apoE2-, E3- andE4- containing particles in the presence of 8µg His-RAP-myc. Detection was 
performed using anti-apoE antibody (lanes 2-4) and anti-His antibody (lanes 5-7). Lane 8 depicts the 
binding of His-RAP-myc to LR8 in the absence of competitor. Anti-LR8 antibody (lane 1) was used to 
visualize LR8 in the ovarian follicle membrane extract. The positions of migration (kDa) of marker 
proteins are indicated. 
 
 
 
To further investigate the receptor- ligand interaction between LR8 and apoE, a competition 
assay was performed in order to determine whether apoE3 can be displaced from LR8 by its 
physiological ligand, VLDL. Blood of roosters was used for the preparation and isolation of 
plasma VLDL fractions. In order todemonstrate the protein constituents present on these 
particles, the isolated lipoprotein fractions were analyzed by SDS-PAGE under reducing 
conditions. Coomassie staining identified a protein band with an apparent molecular weight 
of approx. 500 kDa. Via Western Blot analysis, this band was identified as chicken apoB, the 
major protein constituent of VLDL and LDL particles. Consistent with the fact that ApoVLDL-
II, the second major protein component of VLDL particles, is not produced in roosters and 
immature hens, this apolipoprotein was not present in the isolated fraction (Schneider, W.J., 
Carroll, R. et al. 1990). 
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Figure 3.7 SDS-PAGE analysis of plasma VLDL 
Plasma VLDL fractions were prepared as described in materials 
and methods. 1µg (lane 1), 2 µg (lane 2), and 3 µg (lane 3) 
protein were loaded and separated on 6% polyacrylamide gels 
under reducing conditions. The gel was either stained with 
Coomassie brilliant blue (left panel) or subjected to Western 
Blot analysis (right panel) using anti-ggapoB antibody. The 
positions of migration (kDa) of marker proteins are indicated. 
 
 
Using these chicken lipoproteins as competitive ligands, I employed a direct binding assay 
incubating follicle detergent extracts with constant concentrations of apoE-containing lipid 
particles and increasing concentrations of VLDL. Since apoE3 is the isoform bearing the 
highest receptor affinity (see fig. 3.5), the competition assay was conducted with apoE3-
containing particles. The results obtained from competition assays are shown in figure 3.8 
and revealed the ability of VLDL particles to effectively displace apoE3 from the receptor 
binding site of LR8. This is an indication that both ligands may bind to closely spaced or 
identical receptor sites and when both ligands, apoE and VLDL, are present they compete 
for the binding to the receptor. Consequently, high concentrations of the one ligand (VLDL 
in this assay) lead to a reduction of binding of the second ligand (apoE3). As expected, the 
presence of rooster HDL in the incubation mixtures had no significant inhibitory effect on 
the receptor binding of apoE3, as the apoE-, apoE-free rooster HDL is known not to interact 
with LR8 (Steyrer, E., Barber, D.L. et al. 1990).  
Figure 3.8 Competition of apoE3 and VLDL for the binding to ggLR8  
The competitive assay was performed using an ELISA-based microtiter binding assay. 25 µg small 
white follicle membrane extract (100 µl) and apoE3-containing lipid particles (25 µg/ml protein) were 
incubated in the presence of increasing concentrations of plasma VLDL (filled circles) or HDL (filled 
squares). The amount of receptor-bound apoE3 was determined as described above.  
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3.3 MOLECULAR CHARACTERIZATION OF ggLDLR-APOE INTERACTION 
Despite the structural similarity between the ggLDLR and LR8, their ligand-binding properties 
differ considerably. While LR8 binds apoB, apoE, and VTG, the ggLDLR binds solely to apoB-
containing lipoproteins and prefers chicken LDL over VLDL as ligand (Hummel, S., Lynn, E.G. 
et al. 2003). This is interesting, since avian LDL and VLDL particles do not differ in the content 
of apolipoproteins that participate in receptor binding. The precise underlying mechanism 
for this binding behaviour remains to be investigated.   
As a member of the LDLR family, the chicken LDL receptor constitutes the only LDL receptor 
that binds apoB but not apoE (Bujo, H., Hermann, M. et al. 1997). To confirm the inability of 
the chicken LDLR to bind to apoE I performed ELISA binding assays (figure 3.9).  
 
Based on the finding that upon estrogen administration hepatic LDL receptor levels are 
significantly increased in roosters (Hummel, S., Lynn, E.G. et al. 2003) I prepared total 
protein extracts of livers from estrogen-treated roosters. To confirm the ligand-binding 
competence of the ggLDLR in the liver extract, the binding of physiological binding partners, 
namely VLDL and LDL, was tested. Figure 3.9 shows that the VLDL fraction was able to 
interact with the receptor, confirming both the presence and receptor binding activity of 
chicken LDLR. Additionally, the presence of ggLDLR in the liver extracts was shown by 
Western Blot analysis using a specific antibody against the ggLDLR (data not shown).  
 
 
Figure 3.9 Binding of apoE-containing particles to ggLDLR 
For the binding assay, 100 µg liver extract of estrogen-treated rooster was coated per well and 
incubated with the indicated concentrations of apo E2-, E3-, E4 -containing particles. Detection was 
performed according to materials and methods. Each data point represents the average of duplicate 
determinations.  
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3.4 MUTANGENESIS OF THE ggLDLR LIGAND-BINDING DOMAIN 
The features of the human LDLR necessary for the recognition of apoE have been 
investigated extensively in the past. According to these studies, we especially focused on the 
5th LA repeat in the ligand-binding region, which was repeatedly reported as absolutely 
necessary for apoE-binding (Russell, D.W., Brown, M.S. et al. 1989). The human receptor 
sequence harbors in LA repeat 5 a cluster of negatively charged residues consisting of the 
peptide ser-asp-glu-glu (SDEE), while the corresponding cluster in the chicken LDLR contains 
ser-asp-glu-asp (SDED) (figure 3.1). By replacing glutamic acid (E) with aspartic acid (D) we 
generated a receptor fragment with mutant ligand-binding domain. Furthermore, another 
cluster of acidic residues was taken into account. The sequence alignment of human LDLR 
and ggLR8 (figure 3.1) displays a perfect correlation in the first LA repeat including the 
cluster ser-asp-glu-ser (SDES). The chicken LDLR shows a difference in this sequence by 
containing ser-asp-glu-glu (SDEE) instead of ser-asp-glu-ser (SDES). Since the human LDLR 
binds apoE and the chicken LDLR does not, we altered the ggLDLR sequence according to the 
apoE-binding receptor. Finally, the 28 amino acid linker region of the ggLDLR was shortened 
to a length of 9 residues, since we hypothesized that the prolonged distance between LA 
repeats 4 and 5 may have an impact on the structure and function of the ligand-binding 
domain.  
 
 
Cloning and mutagenesis of ggLDLR LA domain 
The ligand-binding domain of the chicken LDL receptor ggLDLR LA1-7 has been cloned 
previously by Bajari et al. (Bajari, T.M., Strasser, V.et al. 2005). The fragment comprising the 
residues 16-327 of the extracellular receptor domain was cloned in the bacterial expression 
vector pMal2b providing the recombinant protein with an N-terminal maltose-binding 
protein (MBP) and a HIS- tag at the C-terminal end. The predicted molecular weight of the 
fusion protein is 75 kDa.  
 
 
 
 
For site-directed mutagenesis, the vector pMAL containing LA repeats 1-7 of the ggLDLR was 
used as a template for the amplification reaction. In order to verify the presence and correct 
localization of point mutations and deletions, the plasmid DNA was subjected to sequencing.  
By aligning the obtained sequences with the wild type ligand-binding domain, I could 
confirm that all plasmids contained the correct inserts with the corresponding mutations. 
The receptor fragments were designated according to the localization of the introduced 
mutations. LA7m5 was generated by the substitution of aspartatic acid (D) to glutamatic acid 
(E) within the LA repeat 5. LA7del is characterized by the shortened linker region between LA 
4 and LA5. LA7m constitutes a receptor mutant with a substitution of glutamic acid (E) by 
N C gg LDLR LA1-7 MBP 6xHIS 
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serine (S) within LA repeat 1. LA7dbl harbours a double mutation, one being the same as in 
LA7m, the second mutation is the same as in LA7m5, where aspartatic acid (D) is replaced 
with glutamic acid (E) in repeat 5.  
 
 
 
 
humanLDLR MGPWGWKLRWTVALLLAAAGTAVGDRCERNEFQCQDGKCISYKWVCDGSAECQDGSDESQ 60
chickenLDLR MAAWALLLGVLLSAA------TDVWGCDPEQFRCGDGGCISATWVCDGGTECRDGSDEEP 54
humanLDLR ETCLSVTCKSGDFSCGGRV--NRCIPQFWRCDGQVDCDNGSDEQGCPPKTCSQDEFRCHD 118
chickenLDLR EMCRSLQCPAQHFDCGDAVGRERCVPLSWRCDGHRDCRHGADEWGCEPPPCASDQQRCSD 114
humanLDLR GKCISRQFVCDSDRDCLDGSDEASCPVLT-CGPASFQCNSSTCIPQLWACDNDPDCEDGS 177
chickenLDLR GSCVSRAFLCDGDRDCPDGGDERDCPPPPPCPPASFRCPDGVCVDPAWLCDGDADCADGA 174
humanLDLR DEWPQRCRGL----------------YVFQGDSSPCSAFEFHCLSGECIHSSWRCDGGPD 221
chickenLDLR DERSPTCAEATAAEAEAAEAEAEEGEGVVPRPAQRCPPLRVPCRSGGCVPRGWRCDGSPD 234
humanLDLR CKDKSDEENCAVATCRPDEFQCSD-GNCIHGSRQCDREYDCKDMSDEVGCVNVTLCEGPN 280
chickenLDLR CSDGSDEDGCDPPLCPPEEFRCADDGRCVWGGRRCDGHRDCADGSDEDGCDNAPSCVGPD 294
humanLDLR KFKCHSGECITLDKVCNMARDCRDWSDEPIKECGTNECLDNNGGCSHVCNDLKIGYECLC 340
chickenLDLR VFQCRSGECIPTERLCDGRRHCRDWSDEPLQHCDVDECSQGTSGCSHGCQDRPIGFRCLC 354
1
2
3 4
5
6
7
linker
 
 
Figure 3.10 Protein sequences of human and ggLDLR LA repeats 1-7  
Mutations generated by site-directed mutagenesis are indicated with boxes and the resulting protein 
designations (LA7m, LA7del, LA7m5, LA7dbl) are indicated in colours. The alignment starts with the 
methionine residue corresponding to the initiation codon. The signal peptide cleavage site is 
indicated with an arrow.  
  
 
Expression and folding of mutant receptor fragments  
Transformation into E. coli expression strains and protein expression were performed as 
described in materials and methods. Since the expressed receptor fragments contained a 6x 
His-tag on its C- terminus, a metal affinity chromatography based on the high affinity of His 
residues to Ni- ions was used in order to purify the recombinant proteins. Samples of the 
eluted fractions were analyzed by SDS-PAGE under reducing conditions and, to visualize 
proteins, subsequently stained with Coomassie blue. In addition to the receptor mutants 
described above, the wild type ligand-binding domain, which provided the basis for 
mutagenesis was also expressed and purified.   
SDEE → SDES = LA7m 
delete linker → LA7del 
SDED → SDEE = LA7m5 
LA7m + LA7m5 → LA7dbl 
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Figure 3.11 Purification of non-mutated ggLA7 
domain (LA7 wt) and mutated ggLA7 domains 
(LA7m, LA7m5, LA7del, LA7dbl)  
During purification via affinity chromatography, 
various samples were taken and subjected to 7.5% 
SDS-PAGE under reducing conditions. The gels were 
stained with Coomassie blue.   
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As depicted in figure 3.11, the expression level of LA7m5 turned out to be much lower than 
that of the other receptor fragments. Various atempts to optimize conditions during 
expression, e.g., increasing the imidazole concentration, reducing growth temperature, and 
increasing the concentration of antibiotics did not succeed. Consequently I excluded this 
receptor and proceeded with the remaining ones.  
 
 
Since the receptor proteins were expressed in bacterial cells, which do not post-
translationally modify proteins in the same manner as eukaryotes, protein expression was 
followed by a refolding procedure. Thereby, refolding was achieved by the assistance of 
Receptor-associated protein (RAP), the molecular chaperone for the LDLR family. For this 
purpose, I expressed and purified recombinant His-RAP-myc protein and immobilized a 
certain amount on CNBr- activated Sepharose beads. The process of protein coupling was 
verified by SDS-PAGE and Coomassie staining (figure 3.13).   
 
Figure 3.12 Immobilization of His-RAP-myc 
Appropriate amounts of bacterially expressed and purified RAP were coupled to CNBr-activated 
Sepharose. To confirm the coupling efficiency, 25 µl beads were mixed with Laemmli buffer, heated 
to 95°C and subjected to 12% SDS-PAGE (lane 2). Additionally, 10 µg uncoupled, purified His-RAP-myc 
was loaded onto the gel (lane 1). Coomassie blue staining was used in order to visualize proteins.   
 
 
To obtain receptors with a functional, correctly folded ligand-binding domain, the 
recombinant receptors were dialyzed in the presence of RAP-Sepharose under conditions 
that allow disulfide bond formation and Ca2+ incorporation. As correctly folded proteins 
were expected to remain bound to RAP, the receptor fragments were eluted from the resin. 
Eluted fractions were analyzed via SDS-PAGE to test for the purity and folding of the ggLDLR 
fragments (figure 3.14). Coomassie blue staining and Western Blot analysis revealed a 
significant difference in electrophoretic mobility between reduced and native proteins. After 
reduction with 25mM DTT, the obtained band had a size of ~ 90 kDa and was comparable 
with the band observed during purification. However, under non-reducing conditions the 
proteins migrated faster, representing a band at ~ 75 kDa. This significant difference in 
electrophoretic mobility is a hallmark for the folding of the cysteine-rich ligand-binding 
domain or repeats within it. Formation of disulfide bonds within the individual LA repeats 
leads to a more compact structural organization and consequently facilitates migration 
through the gel matrix. The observation that the various fragments displayed a distinct 
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mobility during electrophoresis allowed the conclusion that RAP assisted in the folding of 
LDL receptor fragments.  
 
 
 
 
Figure 3.13 Comparison of receptor fragments under reducing and non-reducing conditions 
2 µg of each ggLDL receptor protein was separated under reducing (R) and under non-reducing (NR) 
conditions on a 7.5% SDS polyacrylamide gel. Proteins were visualized by Coomassie blue staining 
(left anel) and by immunodetection using anti-His antibody followed by HRP-conjugated goat anti-
mouse antibody and ECL detection (right panel).  
 
 
 
In order evaluate the potential of various receptor fragments to bind RAP, an aliquot of the 
eluted fractions were incubated with recombinant, purified His-RAP-myc. Co-
immunoprecipitations were performed using monoclonal anti-myc antibodies. The 
immunoprecipitates were washed, dissolved in Laemmli buffer and subjected to SDS-PAGE 
followed by autoradiography. The results shown in figure 3.15 demonstrate that all receptor 
fragments were capable to bind RAP. Thus, the result of the co-immunoprecipitation 
experiment suggests that the in-vitro folding procedure via binding to RAP acting as 
molecular chaperone indeed leads to active ligand-binding domains.   
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Figure 3.14 Co-Immunoprecipitation: RAP binds to refolded ggLDL receptor fragments 
Receptor fragments (LA7wt, LA7m, LA7del, LA7dbl) obtained from the re-folding procedure (15 µg) 
were incubated with 15 µg purified His-RAP-myc. Co-immunoprecipitations were performed using 
monoclonal anti-myc antibodies and Protein-A Sepharose beads. After intensive washing of the 
beads, reducing Laemmli buffer was added and the mixtures were incubated for 10 min at 95°C. The 
supernatants were subjected to 7.5% SDS-PAGE and subsequent Western blot analysis using anti-
ggLA1-7 antiserum. HRP-conjugated goat anti-rabbit antibody was used as secondary antibody, and 
visualization was performed using ECL.  
 
 
 
 
Next I investigated, whether the introduction of mutations in the ligand-binding domain of 
the chicken LDLR had any impact on receptor function. For this purpose the binding of the 
two receptor ligands apoB and apoE was assessed by the ELISA-based solid phase binding 
assay. Isolated plasma VLDL derived from adult roosters were incubated in microtiter plates 
coated with equal amounts of purified, re-folded receptor fragments. The amount of bound 
VLDL particles was determined by the use of polyclonal antibodies directed against a 
fragment within chicken apoB-100, the major apolipoprotein component on these 
lipoproteins. Figure 3.16 clearly demonstrates that the unmodified ggLDLR ligand-binding 
domain (LA7wt) exhibits the highest binding of chicken VLDL. For LA7m a slightly lower 
binding could be observed. On the contrary, LA7del and LA7dbl were demonstrated to be 
dramatically impaired in binding to VLDL particles. Normalization of the obtained binding 
affinities to the binding of LA7wt revealed that LA7m retained a binding capacity of 82%, 
while the binding of LA7del and LA7dbl was diminished to approximately 20% for both.   
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Figure 3.15 Binding of chicken VLDL to non-mutated ggLA domain (LA7 wt) and mutated ggLA 
domains (LA7m, LA7del, LA7dbl) 
Left panel: Microtiter plates were coated with 2µg of the respective refolded receptor fragment and 
incubated with increasing concentrations of plasma VLDL. Captured VLDL-ApoB was determined 
using a polyclonal antibody against chicken apoB, followed by HRP-conjugated goat anti-rabbit 
antibody according to materials and methods. All data are the average of duplicate determinations. 
Right panel: The results from the ELISA binding assay are plotted as %-age of the binding of the wild 
type ggLDLR ligand-binding domain (LA7wt, 100%).  
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4. DISCUSSION 
The biosynthesis of lipoprotein receptors belonging to the family of LDL receptor relatives 
(LR) is a complex, challenging process as the functionality of these molecules totally depends 
on the correctly folded structure of cysteine-rich domains. The ligand-binding domain 
consists of various numbers of highly conserved cysteine-rich repeats, whose conversion into 
a native, biologically active conformation includes the formation of disulfide bonds as well as 
the incorporation of Ca2+ ions. The efficient folding process requires the assistance of 
enzymes and molecular chaperones residing in the endoplasmatic reticulum (ER). 
The role of RAP as molecular chaperone for members of the LDL receptor family is well 
established. RAP is considered to be an important determinant during the process of 
receptor folding. RAP binds to all LDLR family members and remains associated during 
receptor trafficking through the secretory pathway. However, RAP-assisted folding was 
shown to have a different importance in various cells and tissues. This indication was derived 
from RAP-knockout mice, in which the level of LDLR expression in the liver was unaffected, 
but was downregulated in the brain (Willnow, T.E., Rohlmann, A. et al. 1996; Veinbergs, I., 
Van Uden, E. et al. 2001). Furthermore, studies in the chicken revealed that the expression 
of RAP correlates with the expression of LR8 isoforms in chicken cells (Lindstedt, K.A., 
Mahon, M.G. et al. 1997). The level of RAP was shown to correlate positively with the splice 
variant LR8+, expressed in somatic cells (containing the O-linked sugar domain), while no 
apparent correlation to the LR8- variant (lacking the O-linked sugar domain), found on the 
surface of oocytes, could be determined. A likely explanation for the co-localization of LR8+ 
and RAP in somatic cells, e.g. granulosa cells, is that these cells produce other 
apolipoproteins and potential ligands of the LDL receptor family. RAP has been suggested to 
prevent the premature binding of these ligands during receptor biogenesis and trafficking to 
the cell surface. However, oocytes are not known to synthesize apolipoproteins that may act 
as ligand for LR8-. Consequently, LR8- does not seem to be dependent on RAP-assisted 
prevention of interactions with endogenous ligands. Nevertheless, this variant of LR8 is as 
well capable to interact with RAP as it is shown in figure 3.6, lane 8. RAP is believed to bind 
to the LA-binding repeats within the extracellular domain of the receptor, which is 
supported by the competitive displacement of ligands from LR8 by intracellular RAP 
(Hiesberger, T., Hermann, M. et al. 1995). This antagonistic feature of RAP was also observed 
in the current investigations, as the binding of apoE isoforms to LR8 was abolished upon 
incubation with RAP (figure 3.6, lanes 2-4). 
 
In vitro studies of receptors belonging to the LDLR family require the maintenance of the 
same disulfide bonded structures as produced by the cellular synthetic machinery, a difficult 
aspect of working with the cysteine-rich domains of LRs. Simmons et al. published a protocol 
for the refolding of a functionally active ligand-binding domain of the human LDLR produced 
in bacterial cells (Simmons, T., Newhouse, Y.M. et al. 1997).  Taking into account that correct 
folding requires various critical factors, such as the presence of Ca2+, a relatively high pH 
value (> 8.0) and the addition of a thiol exchange system, they converted the recombinant, 
purified receptors into a folded conformation. To enrich the proteins that are active in ligand 
recognition, they used LDL affinity chromatography. However, the recovery of correctly 
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folded receptor was reported to be low (Marlovits, T.C., Abrahamsberg, C.et al. 1998). In 
other studies, immobilized receptor-associated protein (RAP) was successfully used to 
promote and increase the folding efficiency of recombinant VLDL receptors (Ronacher, B., 
Marlovits, T.C. et al. 2000).  
Here, I applied RAP-coupled Sepharose in the re-folding process of chicken LDLR fragments. 
Bacterially expressed receptor ligand-binding domains were incubated in the presence of 
RAP-Sepharose under conditions that allow the formation of disulfide bonds and the 
incorporation of Ca2+. To investigate the correct folding and functionality of the receptor 
fragments, solid phase binding assays were performed using apoB-harboring VLDL particles, 
which are well characterized as ligands for the ggLDLR under physiological conditions. The 
receptor fragment consisting of the ligand-binding domain of the chicken LDLR was capable 
to bind to apoB-containing plasma lipoproteins (figure 3.16).  Thus, the refolding procedure 
into biologically active receptor fragments was concluded to have been successful. 
 
Besides apoB, apoE constitutes the second major ligand for the mammalian LDLR. Notably, 
apoE does not bind to the LDLR with high affinity unless it is associated with lipids. A key 
characteristic of the human LDLR is that it differentially recognizes apoE-containing lipidated 
particles depending on which apoE-isoform is present. The three apoE isoforms E2, E3, and 
E4 differ from each other by single amino acid substitutions that were characterized to have 
a great impact on structure, function, and lipid profiles in humans. ApoE3 shows the highest 
receptor binding activity, followed by apoE4 with modest binding, while E2 displays a 
significantly decreased ability to bind to human LDLR. The data obtained from solid phase 
binding assays (figure 3.3) reflect the previously observed binding behavior of human LDLR 
to the distinct apoE-isoforms. 
 
Studies in the model organism chicken have revealed apolipoprotein E as a mammalian 
counterpart to the chicken yolk precursor vitellogenin. Although not existing in the avian 
species, apoE was shown to bind to the chicken oocyte receptor LR8 (Steyrer, E., Barber, D.L. 
et al. 1990). Conversely, vitellogenin, which is absent in humans can bind to certain 
members of the mammalian LDL receptor gene family, namely the LDLR and LRP1 (Stifani, S., 
Barber, D.L. et al. 1991). Comparative analyses revealed homologous segments between VTG 
and apoE that are necessary to mediate receptor binding (Steyrer, E., Barber, D.L. et al. 
1990). Moreover, both receptors bind apolipoprotein B-100-containing lipoproteins, 
whereas the avian receptor even binds to VLDL and LDL of mammalian origin, albeit with 
lower affinity (George, R., Barber, D.L. et al. 1987). 
Besides the similar lipoprotein specificities, several findings emphasize additional similarities 
between the two receptors from different species. Immunological relationship was 
established as polyclonal antibodies directed against the purified bovine LDLR cross-react 
with both the human LDLR and the chicken oocyte receptor LR8  (George, R., Barber, D.L. et 
al. 1987). Apart from the different molecular weight, the mammalian LDLR is more akin to 
the chicken LR8 than to its functional homologue, the chicken LDLR. This receptor is involved 
in the regulation of cholesterol homeostasis in somatic cells analogous to the mammalian 
LDLR but in turn this receptor binds to apoB- but not to apoE-containing lipoproteins.  
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In my diploma thesis I now applied ELISA- and co-immunoprecipitation methodology to 
confirm previous observations that chicken LR8 has the ability to interact with apoE. 
However, unlike the human LDLR LR8 discriminates less against the isoforms apoE2 (figure 
3.5). Competitive binding assays with plasma VLDL demonstrated that apoE3 competed with 
plasma VLDL for the binding to LR8. This observation indicates that apoE and apoB bind to 
closely spaced or even identical sites within the receptor.  
Solid phase binding assays using chicken tissue extracts as a source of chicken LDLR showed 
the inability of this receptor to interact with apoE-containing ligands (figure 3.9). Based on 
prior mutational analysis I selected potential binding-reactive sites within the ligand-binding 
domain of the chicken LDLR, and applied site-directed mutagenesis with the primary 
objective to delineate defined sequence motifs that contribute to the binding of apoE-
containing ligands, and possibly to create receptor fragments that have gained apoE-binding 
capacity. 
The different mutated ggLDLR ligand-binding domains were expressed, re-folded in the 
presence of RAP and subjected to ELISA-based binding. According to the differential binding 
characteristics of the different mutated ggLDLR ligand-binding domains, it can be reasoned 
that the first LA repeat seems not to be involved in the binding of VLDL via apoB. On the 
contrary, the alteration of the cluster from SDED to SDES in LA5 had a significant impact on 
the binding behaviour by reducing VLDL binding to 20% relative to wild type receptor 
binding. These findings are in agreement with multiple previous investigations suggesting 
that LA repeat 1 does not participate in apoB binding, while the other repeats are critical for 
the interaction with this ligand.  
The ligand-binding domain of the ggLDLR is built up by seven adjacent LA-repeats that are 
separated from each other by short linker regions of 4-5 residues with exception of the LA4-
5 module pair, which is linked by a much longer region (28 residues). Shortening the linker 
region between LA repeat 4 and 5 from 28 to 9 residues (the length of the linker in the 
human LDLR) lowers VLDL binding approximately to the same degree (22% normalized to wt 
receptor binding). In general, the linker regions are thought to confer flexibility and to 
contribute to the ability to bind a diverse range of protein- and lipoprotein ligands. The 
observed reduction of binding upon shortening the repeat-spanning region between LA4 and 
5 implies that it seems necessary to keep a certain distance between these two repeats in 
order to confer high binding affinity for apoB-containing ligands.  
Unfortunately, initial investigations examining the binding activity of the purified, refolded 
receptor fragments towards apoE-containing particles did not lead to reproducible results 
(not shown), possibly due to the difficulty in obtaining sufficient amounts of active receptor. 
Thus, to obtain a better basis for future experiments, an efficient alternative for receptor 
protein expression would be cells other than bacteria that allow posttranslational 
modifications as well as protein folding in vivo. 
 
 
A further point concerns the specific biophysical properties of apoE. Until recently it was 
assumed that apoE must be associated with lipids in order to confer high receptor binding 
affinity. Recently, the interaction of apoE with two other members of the human LDL 
receptor family, LRP1 and VLDL receptor, were investigated (Ruiz, J., Kouiavskaia, D.et al. 
2005). It was reported that both receptors bound apoE, but unlike the LDLR they do not 
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discriminate between the apoE isoforms. However, the interaction of apoE with the VLDLR 
displayed asignificant difference in that it recognizes all isoforms also in a lipid-free state. 
This finding proposes that the binding of apoE in the lipid-bound versus lipid-free state may 
be of physiological significance and may relate to distinct functions of apoE-binding 
receptors. In general, despite the ever increasing knowledge about the multiple roles of 
apolipoprotein E, both in the plasma and central nervous system, extensive further studies 
will be required to completely understand the complexity of the functions of apoE and ApoE-
receptors.  
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α    alpha, anti 
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ACAT    Acyl-CoA:cholesterol acyltransferase 
AD   Alzheimer’s disease 
Amp    ampicillin 
Apo    apolipoprotein 
APS    ammonium persulfate 
 
bp    base pair 
BSA    bovine serum albumin 
 
C    cytosine or Celsius 
CaCl2    calcium chloride 
cDNA    complementary DNA 
CE    cholesterolester 
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CNBr    cyanogen bromide 
C-terminus   carboxy-terminus 
 
Da    Dalton 
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HSPG    heparan sulfate proteoglycane 
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kDa    kilo dalton 
 
l    liter 
LA    type A ligand-binding domains 
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LDL    low-density lipoprotein 
LDLR    low-density lipoprotein receptor 
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LPL    lipoprotein lipase 
LR8  low-density lipoprotein receptor related protein with 8 ligand-binding 
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LRP    low-density lipoprotein receptor related protein 
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μl    microliter 
M    molar  
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min    minute 
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mM    millimolar 
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Ni-NTA   nickel nitriloacetic acid 
nm    nanometer 
nt    nucleotides 
N-terminal   amino-terminal 
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OD    optical density 
 
PAA    polyacrylamide 
PAGE    polyacrylamide gel electrophoresis 
PBS    phosphate-buffered saline 
PCR    polymerase chain reaction 
PSCK9   proprotein convertase subtilisin-like kexin type 9 
 
R/O    restricted ovulator 
RAP    receptor associated protein 
rev    reverse 
RNA    ribonucleic acid 
rpm    rounds per minute 
RT    room temperature 
 
SDS    sodium dodecyl sulfate 
sec    second 
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